var title_f11_58_12192="Herpes zoster rash 1 PI";
var content_f11_58_12192=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F50627&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F50627&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Shingles (herpes zoster)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 351px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Vaibhav Parekh, MD, MBA.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_58_12192=[""].join("\n");
var outline_f11_58_12192=null;
var title_f11_58_12193="Dry tongue in SS";
var content_f11_58_12193=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F51074&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F51074&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Severe xerostomia with dry tongue and angular chelitis in Sj&ouml;gren's syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This patient with Sj&ouml;gren's syndrome not only has a profoundly dry tongue, but there is also evidence of angular cheilitis at the corners of the mouth. Angular cheilitis is usually caused by candidiasis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert Fox, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_58_12193=[""].join("\n");
var outline_f11_58_12193=null;
var title_f11_58_12194="Patient information: Chronic myeloid leukemia (CML) (The Basics)";
var content_f11_58_12194=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?2/47/2802\">",
"         Patient information: Bone marrow transplant (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?37/13/38098\">",
"         Patient information: Leukemia in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?34/4/34886\">",
"         Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?36/60/37829\">",
"         Patient information: Chronic myeloid leukemia (CML) in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Chronic myeloid leukemia (CML) (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/chronic-myeloid-leukemia-cml-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H13397085\">",
"      <span class=\"h1\">",
"       What is chronic myeloid leukemia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Chronic myeloid leukemia, called &ldquo;CML,&rdquo; is a type of blood cancer. Blood is made up of different types of cells. These cells are made in the middle of your bones, in a part called the bone marrow.",
"     </p>",
"     <p>",
"      People with CML have an abnormal gene in some of their blood cells. This gene causes the bone marrow to make abnormal blood cells. These abnormal blood cells can grow out of control, get into the blood, and travel around the body. Sometimes, these cells collect in certain parts of the body.",
"     </p>",
"     <p>",
"      When the bone marrow makes abnormal blood cells, it does not make enough of the normal blood cells a person&rsquo;s body needs. This can cause symptoms.",
"     </p>",
"     <p>",
"      There are 3 stages, or &ldquo;phases,&rdquo; of CML:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        During the",
"        <strong>",
"         chronic phase",
"        </strong>",
"        , the cancer grows very slowly. Most people are in this phase when their CML is diagnosed. This phase can last for years.",
"       </li>",
"       <li>",
"        During the",
"        <strong>",
"         accelerated phase",
"        </strong>",
"        , the cancer begins to grow faster.",
"       </li>",
"       <li>",
"        During the",
"        <strong>",
"         blast phase",
"        </strong>",
"        , the cancer is fast-growing and can be fatal.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Treatment depends, in part, on the phase of your CML.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13397092\">",
"      <span class=\"h1\">",
"       What are the symptoms of CML?",
"      </span>",
"      &nbsp;&mdash;&nbsp;CML does not always cause symptoms, especially at first. When it does cause symptoms, the most common ones are:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Feeling very tired and weak",
"       </li>",
"       <li>",
"        Sweating much more than usual, or losing weight without trying to",
"       </li>",
"       <li>",
"        Feeling full after eating a small amount of food",
"       </li>",
"       <li>",
"        Bleeding more easily than normal",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13397099\">",
"      <span class=\"h1\">",
"       Is there a test for CML?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Your doctor or nurse will talk with you, do an exam, and do blood tests. He or she might also do a bone marrow biopsy. For this test, a doctor takes a very small sample of the bone marrow. Then another doctor will look at the cells under a microscope to see if abnormal (cancer) cells are present.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13397106\">",
"      <span class=\"h1\">",
"       How is CML treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Doctors can treat CML in different ways. When CML is first diagnosed and in the chronic phase, it is treated with medicines (pills) called &ldquo;tyrosine kinase inhibitors&rdquo; or &ldquo;TKIs.&rdquo; TKIs kill the blood cells that have the CML abnormal gene. When these blood cells are gone, the bone marrow can work normally again. TKIs do not cure CML, but they can control it for many years. If you take a TKI, it is very important to take every single dose. Skipping pills can allow the CML to grow out of control.",
"     </p>",
"     <p>",
"      If people have too many side effects from their TKI, or if their CML starts to grow faster, they can have other treatments. These can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Another TKI &ndash; Different TKIs have different side effects. Also, one TKI might work better to control your CML than another. If one TKI doesn&rsquo;t work for you, another might.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Chemotherapy &ndash; Chemotherapy is the term doctors use to describe a group of medicines that kill cancer cells.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Bone marrow transplant &ndash; This treatment replaces cells in the bone marrow that are killed by chemotherapy or radiation. (Radiation kills cancer cells.) These &ldquo;donor&rdquo; cells can come from another person whose blood matches yours.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        A type of medicine called &ldquo;interferon alpha&rdquo;",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13397113\">",
"      <span class=\"h1\">",
"       What happens after treatment?",
"      </span>",
"      &nbsp;&mdash;&nbsp;After treatment, your doctor will check you every so often to see if the cancer comes back. Regular follow-ups include talking with your doctor, exams, and blood tests. Sometimes, your doctor will also do a bone marrow biopsy.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13397120\">",
"      <span class=\"h1\">",
"       What happens if the CML comes back?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If the CML comes back, you might be treated with TKIs, chemotherapy, bone marrow transplant, or other medicines.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13397127\">",
"      <span class=\"h1\">",
"       What else should I do?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It&rsquo;s important to follow all your doctor&rsquo;s instructions about visits, tests, and treatment. It&rsquo;s also important to talk to your doctor about any side effects or problems you have during treatment.",
"     </p>",
"     <p>",
"      Getting treated for CML involves making many choices, such as what treatment to have and when.",
"     </p>",
"     <p>",
"      Always let your doctors and nurses know how you feel about a treatment. Any time you are offered a treatment, ask:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        What are the benefits of this treatment? Is it likely to help me live longer? Will it reduce or prevent symptoms?",
"       </li>",
"       <li>",
"        What are the downsides to this treatment?",
"       </li>",
"       <li>",
"        Are there other options besides this treatment?",
"       </li>",
"       <li>",
"        What happens if I do not have this treatment?",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13397134\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?37/13/38098?source=see_link\">",
"       Patient information: Leukemia in adults (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?2/47/2802?source=see_link\">",
"       Patient information: Bone marrow transplant (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?36/60/37829?source=see_link\">",
"       Patient information: Chronic myeloid leukemia (CML) in adults (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?34/4/34886?source=see_link\">",
"       Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?11/58/12194?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15792 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-58.240.65.66-4367187BB2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_58_12194=[""].join("\n");
var outline_f11_58_12194=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13397085\">",
"      What is chronic myeloid leukemia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13397092\">",
"      What are the symptoms of CML?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13397099\">",
"      Is there a test for CML?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13397106\">",
"      How is CML treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13397113\">",
"      What happens after treatment?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13397120\">",
"      What happens if the CML comes back?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13397127\">",
"      What else should I do?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13397134\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?2/47/2802?source=related_link\">",
"      Patient information: Bone marrow transplant (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/4/34886?source=related_link\">",
"      Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?36/60/37829?source=related_link\">",
"      Patient information: Chronic myeloid leukemia (CML) in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/13/38098?source=related_link\">",
"      Patient information: Leukemia in adults (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_58_12195="Schematic of transmyocardial laser revascularization";
var content_f11_58_12195=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F68481&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F68481&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 494px\">",
"   <div class=\"ttl\">",
"    Schematic of percutaneous myocardial revascularization",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 474px; height: 303px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Percutaneous myocardial revascularization can be performed in the catheterization laboratory, via standard femoral artery access without general anesthesia, after a ventriculogram and coronary angiogram demonstrate the left ventricular and coroanry artery anatomy. A steerable catheter is delivered retrograde across the aortic valve; the energy delivery catheter is advanced through the guiding catheter and placed in the ventricular chamber. The steerable catheter allows access to the endocardial surface (left panel). The enlarged area (right panel) shows that intramyocardial channels are made by tissue ablation (red arrow) when the energy delivery catheter is in contact with the endocardium; the channels cause intramyocardial hemorrhage by transecting the microvasculature (blue arrow).",
"    <div class=\"footnotes\">",
"     V: epicardial vein; A: epicardial artery.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Kantor B, McKenna CJ, Caccitolo JA, et al. Mayo Clin Proc 1999; 74:585.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_58_12195=[""].join("\n");
var outline_f11_58_12195=null;
var title_f11_58_12196="Vitiligo - lips";
var content_f11_58_12196=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F51865&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F51865&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Vitiligo",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 325px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Depigmented patches are present on the lips of this patient with vitiligo.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_58_12196=[""].join("\n");
var outline_f11_58_12196=null;
var title_f11_58_12197="NSAIDs (including aspirin): Secondary prevention of gastroduodenal toxicity";
var content_f11_58_12197=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   NSAIDs (including aspirin): Secondary prevention of gastroduodenal toxicity",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/58/12197/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/58/12197/contributors\">",
"     Mark Feldman, MD, MACP, AGAF, FACG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/58/12197/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/58/12197/contributors\">",
"     J Thomas LaMont, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/58/12197/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/58/12197/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/58/12197/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 3, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonselective (ie, inhibiting both cyclooxygenase [COX]-1 and COX-2) nonsteroidal antiinflammatory drugs (NSAIDs), including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , cause considerable morbidity and mortality related to gastric and duodenal ulcer disease, particularly gastrointestinal (GI) bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?11/58/12197/abstract/1\">",
"     1",
"    </a>",
"    ]. Even low-dose aspirin is associated with an increase in risk [",
"    <a class=\"abstract\" href=\"UTD.htm?11/58/12197/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prevention of recurrent gastroduodenal toxicity associated with NSAID therapy (secondary prevention) will be reviewed here. Primary prevention and treatment of NSAID-related gastroduodenal toxicity are discussed separately as is the pathogenesis of the gastroduodenal toxicity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38393?source=see_link\">",
"     \"NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/20/26947?source=see_link\">",
"     \"NSAIDs (including aspirin): Treatment of gastroduodenal toxicity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/37/6745?source=see_link\">",
"     \"NSAIDs (including aspirin): Pathogenesis of gastroduodenal toxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SECONDARY PREVENTION OF GASTRODUODENAL TOXICITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prevention of ulcer disease becomes important in patients with a history of gastroduodenal toxicity from nonsteroidal antiinflammatory drugs (NSAIDs) who require continued NSAID therapy, including those treated with low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    for cardiovascular protection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     With continued NSAID therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are some patients who must resume or continue NSAID therapy despite prior development of gastroduodenal ulcers or erosions. Several randomized trials have evaluated various strategies for treating such patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/58/12197/abstract/3-7\">",
"     3-7",
"    </a>",
"    ]. Considered together they suggest that patients with gastroduodenal ulcers or numerous erosions who must continue NSAID therapy should be treated with a proton pump inhibitor (PPI) for as long as the NSAID or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    is used.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/62/26601?source=see_link\">",
"       Omeprazole",
"      </a>",
"      was found to be superior to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/56/42888?source=see_link\">",
"       ranitidine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"       misoprostol",
"      </a>",
"      , and placebo in maintaining remission [",
"      <a class=\"abstract\" href=\"UTD.htm?11/58/12197/abstract/3,4\">",
"       3,4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Combination therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/62/26601?source=see_link\">",
"       omeprazole",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"       misoprostol",
"      </a>",
"      did not appear to be more effective than omeprazole alone [",
"      <a class=\"abstract\" href=\"UTD.htm?11/58/12197/abstract/8\">",
"       8",
"      </a>",
"      ]. However, in this study, a low, possibly suboptimal dose of misoprostol was used.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    PPI therapy also appears effective in patients who test positive for",
"    <em>",
"     H. pylori",
"    </em>",
"    , and must remain on NSAIDs. In one study of",
"    <em>",
"     H. pylori",
"    </em>",
"    positive patients with NSAID-related ulcer disease from Hong Kong, maintenance therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/62/26601?source=see_link\">",
"     omeprazole",
"    </a>",
"    was more effective in preventing recurrent bleeding than anti-",
"    <em>",
"     H. pylori",
"    </em>",
"    therapy alone [",
"    <a class=\"abstract\" href=\"UTD.htm?11/58/12197/abstract/5\">",
"     5",
"    </a>",
"    ]. A systematic review of studies comparing PPI therapy with a",
"    <em>",
"     H. pylori",
"    </em>",
"    eradication strategy found that a",
"    <em>",
"     H. pylori",
"    </em>",
"    eradication strategy was equally effective with PPI treatment for the prevention of endoscopic ulcers and more effective than placebo in preventing recurrent bleeding from ulcers in NSAID users [",
"    <a class=\"abstract\" href=\"UTD.htm?11/58/12197/abstract/9\">",
"     9",
"    </a>",
"    ]. In clinical practice, patients who are",
"    <em>",
"     H. pylori",
"    </em>",
"    positive are generally treated with a PPI along with",
"    <em>",
"     H. pylori",
"    </em>",
"    eradication. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/10/12455?source=see_link\">",
"     \"Management of duodenal ulcers in patients infected with Helicobacter pylori\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When COX-2 inhibitors were first introduced, these agents appeared to hold promise as an alternative to traditional NSAIDs in preventing recurrent peptic ulcer disease in individuals who required ongoing antiinflammatory therapy. However, the relative risk reduction in gastrointestinal bleeding associated with these agents appears to be modest at best. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38393?source=see_link&amp;anchor=H8#H8\">",
"     \"NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity\", section on 'Selective COX-2 inhibitors'",
"    </a>",
"    .) Replacing a COX-2 inhibitor for the nonselective NSAID in patients with NSAID-related ulcer disease should not be chosen over PPI maintenance therapy. This was demonstrated in one trial in which adding",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/39/15993?source=see_link\">",
"     esomeprazole",
"    </a>",
"    to the NSAID was more effective in preventing recurrent ulcers than replacing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/11/40120?source=see_link\">",
"     celecoxib",
"    </a>",
"    for the NSAID the patient had been on previously [",
"    <a class=\"abstract\" href=\"UTD.htm?11/58/12197/abstract/6\">",
"     6",
"    </a>",
"    ]. COX-2 inhibitors also have other health concerns in regard to cardiovascular risk. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/27/39351?source=see_link\">",
"     \"COX-2 selective inhibitors: Adverse cardiovascular effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     With continued low-dose aspirin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    (75 to 325",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    is of proven benefit in the secondary prevention and, in selected patients, the primary prevention of cardiovascular disease. Patients with low-dose aspirin have an increased risk of gastrointestinal bleeding, which must be weighed against a possible increase in mortality. The risk of recurrent bleeding in aspirin users may be higher in patients without a past or current",
"    <em>",
"     H. pylori",
"    </em>",
"    infection as compared with those with a",
"    <em>",
"     H. pylori",
"    </em>",
"    infection that was eradicated (incidence",
"    <span class=\"nowrap\">",
"     rate/100",
"    </span>",
"    patient-years 5.22 versus 0.97) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/58/12197/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Risk of stopping aspirin'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    However, randomized trials support the efficacy of proton pump inhibitor (PPI) therapy in preventing recurrent bleeding in both",
"    <em>",
"     H. pylori",
"    </em>",
"    positive and negative patients. Different approaches using a PPI to prevent recurrent GI bleeding in patients who continue",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    therapy have been evaluated in at least five randomized trials, all of which were performed in Hong Kong [",
"    <a class=\"abstract\" href=\"UTD.htm?11/58/12197/abstract/5,11-14\">",
"     5,11-14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    All of the placebo-controlled trials showed a significant reduction in recurrent complications with PPI therapy. The trials can be summarized as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among patients infected with",
"      <em>",
"       H. pylori",
"      </em>",
"      , the rate of recurrent ulcer complications was significantly lower at one year with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/14/3305?source=see_link\">",
"       lansoprazole",
"      </a>",
"      (30 mg daily) compared to placebo (1.6 versus 14.8 percent), which were started after the ulcer had healed and",
"      <em>",
"       H. pylori",
"      </em>",
"      was eradicated. [",
"      <a class=\"abstract\" href=\"UTD.htm?11/58/12197/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A similar difference in recurrent bleeding at one year (0.7 versus 8.6 percent) in",
"      <em>",
"       H. pylori",
"      </em>",
"      negative patients was noted with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/39/15993?source=see_link\">",
"       esomeprazole",
"      </a>",
"      (20 mg twice daily) plus low-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      compared to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      (75",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      plus placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?11/58/12197/abstract/12\">",
"       12",
"      </a>",
"      ]. A similar trial stopped early because of a higher bleeding rate in the clopidogrel group [",
"      <a class=\"abstract\" href=\"UTD.htm?11/58/12197/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Two other trials compared different therapies without a placebo group: in one, a PPI (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/16/32009?source=see_link\">",
"       pantoprazole",
"      </a>",
"      ) was associated with a significantly lower rate of recurrent symptomatic or bleeding",
"      <span class=\"nowrap\">",
"       ulcers/erosions",
"      </span>",
"      than an H2-blocker (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/45/728?source=see_link\">",
"       famotidine",
"      </a>",
"      ) (0 versus 20 percent at 48 weeks) [",
"      <a class=\"abstract\" href=\"UTD.htm?11/58/12197/abstract/14\">",
"       14",
"      </a>",
"      ]. In the second trial, which was limited to patients who were H. pylori positive, there was no significant difference in recurrent bleeding at six months with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/62/26601?source=see_link\">",
"       omeprazole",
"      </a>",
"      (20",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      compared to anti-",
"      <em>",
"       H. pylori",
"      </em>",
"      therapy (0.9 versus 1.9 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?11/58/12197/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In summary, patients who have had a bleeding ulcer while taking low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    therapy should be treated with a PPI (rather than an H2-blocker), along with",
"    <em>",
"     H. pylori",
"    </em>",
"    eradication if they test positive for",
"    <em>",
"     H. pylori",
"    </em>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/10/12455?source=see_link\">",
"     \"Management of duodenal ulcers in patients infected with Helicobacter pylori\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are no compelling data that suggest that any of the available PPIs are more effective than another. The table lists the available medications and their usual dose (",
"    <a class=\"graphic graphic_table graphicRef81079 \" href=\"UTD.htm?22/37/23131\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Risk of stopping aspirin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risks and benefits of stopping",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    were addressed in a randomized trial of 156 adults with cardiovascular or cerebrovascular disease who were being treated with low-dose aspirin and developed peptic ulcer bleeding, which was controlled with endoscopic therapy and a PPI [",
"    <a class=\"abstract\" href=\"UTD.htm?11/58/12197/abstract/15\">",
"     15",
"    </a>",
"    ]. The patients were assigned to continue taking aspirin (80",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or to switch to placebo for eight weeks. Aspirin therapy was associated with a nonsignificant increase in recurrent ulcer bleeding within 30 days (10.3 versus 5.4 percent with placebo, difference 4.9 percent, 95% CI 3.6-13.4) and a significant reduction in mortality at eight weeks (1.3 versus 10.3 percent, difference 9 percent, 95% CI 1.7-16.3 ).",
"   </p>",
"   <p>",
"    The magnitude of this mortality benefit is much greater than seen in large randomized trials of secondary prevention with much longer follow-up. In recognition of this difference, the authors concluded that larger trials are needed to confirm these findings. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37066?source=see_link&amp;anchor=H13#H13\">",
"     \"Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease\", section on 'Efficacy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with gastroduodenal ulcers or numerous erosions who must continue nonsteroidal antiinflammatory drug (NSAID) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      therapy, we recommend treatment with a proton pump inhibitor for as long as the NSAID or aspirin is used (",
"      <a class=\"graphic graphic_table graphicRef81079 \" href=\"UTD.htm?22/37/23131\">",
"       table 1",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Secondary prevention of gastroduodenal toxicity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In addition, we recommend that",
"      <em>",
"       H. pylori",
"      </em>",
"      infection be eradicated, if known to be present (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/10/12455?source=see_link\">",
"       \"Management of duodenal ulcers in patients infected with Helicobacter pylori\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23049?source=see_link\">",
"       \"Treatment regimens for Helicobacter pylori\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Selecting",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/11/40120?source=see_link\">",
"       celecoxib",
"      </a>",
"      (or another COX-2 selective agent, if available) plus a proton pump inhibitor may be effective preventing recurrent ulcers, but efficacy of this approach has not been rigorously evaluated and the use of these agents has other health concerns. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'With continued NSAID therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/58/12197/abstract/1\">",
"      Wallace JL. Nonsteroidal anti-inflammatory drugs and gastroenteropathy: the second hundred years. Gastroenterology 1997; 112:1000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/58/12197/abstract/2\">",
"      McQuaid KR, Laine L. Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. Am J Med 2006; 119:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/58/12197/abstract/3\">",
"      Yeomans ND, Tulassay Z, Juh&aacute;sz L, et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med 1998; 338:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/58/12197/abstract/4\">",
"      Hawkey CJ, Karrasch JA, Szczepa&ntilde;ski L, et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med 1998; 338:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/58/12197/abstract/5\">",
"      Chan FK, Chung SC, Suen BY, et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 2001; 344:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/58/12197/abstract/6\">",
"      Chan FK, Wong VW, Suen BY, et al. Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. Lancet 2007; 369:1621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/58/12197/abstract/7\">",
"      Goldstein JL, Johanson JF, Hawkey CJ, et al. Clinical trial: healing of NSAID-associated gastric ulcers in patients continuing NSAID therapy - a randomized study comparing ranitidine with esomeprazole. Aliment Pharmacol Ther 2007; 26:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/58/12197/abstract/8\">",
"      Yilmaz S, Bayan K, Dursun M, et al. Does adding misoprostol to standard intravenous proton pump inhibitor protocol improve the outcome of aspirin/NSAID-induced upper gastrointestinal bleeding?: a randomized prospective study. Dig Dis Sci 2007; 52:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/58/12197/abstract/9\">",
"      Leontiadis GI, Sreedharan A, Dorward S, et al. Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding. Health Technol Assess 2007; 11:iii.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/58/12197/abstract/10\">",
"      Chan FK, Ching JY, Suen BY, et al. Effects of Helicobacter pylori infection on long-term risk of peptic ulcer bleeding in low-dose aspirin users. Gastroenterology 2013; 144:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/58/12197/abstract/11\">",
"      Lai KC, Lam SK, Chu KM, et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med 2002; 346:2033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/58/12197/abstract/12\">",
"      Chan FK, Ching JY, Hung LC, et al. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med 2005; 352:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/58/12197/abstract/13\">",
"      Lai KC, Chu KM, Hui WM, et al. Esomeprazole with aspirin versus clopidogrel for prevention of recurrent gastrointestinal ulcer complications. Clin Gastroenterol Hepatol 2006; 4:860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/58/12197/abstract/14\">",
"      Ng FH, Wong SY, Lam KF, et al. Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions. Gastroenterology 2010; 138:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/58/12197/abstract/15\">",
"      Sung JJ, Lau JY, Ching JY, et al. Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial. Ann Intern Med 2010; 152:1.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-961E418322-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_58_12197=[""].join("\n");
var outline_f11_58_12197=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H6\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SECONDARY PREVENTION OF GASTRODUODENAL TOXICITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      With continued NSAID therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      With continued low-dose aspirin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Risk of stopping aspirin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/12\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/12|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/37/23131\" title=\"table 1\">",
"      Active and maintenance therapy of gastroduodenal ulcers",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37066?source=related_link\">",
"      Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/27/39351?source=related_link\">",
"      COX-2 selective inhibitors: Adverse cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/10/12455?source=related_link\">",
"      Management of duodenal ulcers in patients infected with Helicobacter pylori",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/37/6745?source=related_link\">",
"      NSAIDs (including aspirin): Pathogenesis of gastroduodenal toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38393?source=related_link\">",
"      NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/20/26947?source=related_link\">",
"      NSAIDs (including aspirin): Treatment of gastroduodenal toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23049?source=related_link\">",
"      Treatment regimens for Helicobacter pylori",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_58_12198="Contrast CT panc neck";
var content_f11_58_12198=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F63442&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F63442&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Contrast CT of tumor in pancreatic neck",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 279px; height: 575px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Contrast-enhanced CT axial images of a patient with a solid, ill-defined tumor in the neck of the pancreas (arrow in A). No vascular encasement is observed. However, multiple small hypodense lesions are seen throughout the liver parenchyma (arrows in B and C), which are highly suspicious for metastatic disease.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Rocio Perez-Johnston.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_58_12198=[""].join("\n");
var outline_f11_58_12198=null;
var title_f11_58_12199="HPLC alpha chain variants";
var content_f11_58_12199=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F63052&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F63052&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 584px\">",
"   <div class=\"ttl\">",
"    Alpha chain hemoglobin variants on HPLC",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 564px; height: 488px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cation exchange HPLC pattern of some alpha chain variants. HbA, A2, A",
"    <sub>",
"     1C",
"    </sub>",
"    , F, S, and C are highlighted.",
"    <div class=\"footnotes\">",
"     HPLC: high performance liquid chromatography.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_58_12199=[""].join("\n");
var outline_f11_58_12199=null;
var title_f11_58_12200="Approach to the patient";
var content_f11_58_12200=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Approach to the patient",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/58/12200/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/58/12200/contributors\">",
"     Jeannette M Shorey, II, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/58/12200/contributors\">",
"     John J Spollen, III, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/58/12200/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/58/12200/contributors\">",
"     Suzanne W Fletcher, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/58/12200/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/58/12200/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/58/12200/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In North America, people seek medical services for many different reasons. Medical care for acute or chronic conditions is the principal reason, but patients also increasingly request clinicians' advice about maintaining their health, inquiring about good nutrition, exercise programs, and other strategies to prevent disease. Near the end of life, patients may seek clinician advice on withdrawing from cure-oriented interventions, emphasizing the need for comfort and control of symptoms instead. Finally, people come to clinicians for their role as \"social managers,\" seeking assistance in accessing social goods and services (eg disability benefits, housing benefits, workers' compensation, \"permission\" to return to work, and clearance to participate in athletic activities). Responding to such diverse needs and requests is a substantial challenge.",
"   </p>",
"   <p>",
"    The medical interview is the medium through which the needs and requests are made known, the human connections are established, and almost all the work of doctoring is conducted. As we consider the approach to the \"patient,\" we will focus upon the knowledge, skills, and values that foster effective professional connections with the",
"    <strong>",
"     people",
"    </strong>",
"    who enter clinicians' offices seeking care, some of whom may be sick",
"    <strong>",
"     patients",
"    </strong>",
"    .",
"   </p>",
"   <p>",
"    Today's clinicians have at their disposal a vast and rapidly-growing body of biomedical knowledge. The understanding and appropriate application of this knowledge is a foundation for effective medical care. Two principal tasks of clinicians are to master the knowledge pertinent to their field of medicine and to develop personal strategies to learn continuously and manage the enormous body of information that will continue to evolve throughout their careers [",
"    <a class=\"abstract\" href=\"UTD.htm?11/58/12200/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The appropriate application of biomedical and psychosocial knowledge requires a contextual understanding of each individual who seeks medical care. This in turn requires the ability to communicate effectively with each patient, mindful of the importance of the person's cultural background. Unfortunately, improvements in communication between clinicians and patients, which would require designated time prioritized to effectively interview patients and understand their needs, has not kept pace with technological advances in medicine [",
"    <a class=\"abstract\" href=\"UTD.htm?11/58/12200/abstract/2\">",
"     2",
"    </a>",
"    ]. Clinicians must build and sustain trustworthy relationships in order to hear and grasp patient concerns, elicit their requests, negotiate diagnostic and treatment strategies, teach them about their health or illness, check on adherence to treatment plans, and assess the outcomes of interventions. Thus, the third principal task of clinicians is to heed the admonition of E.M. Forster: \"always connect\" [",
"    <a class=\"abstract\" href=\"UTD.htm?11/58/12200/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Our society has demanded that the medical profession provide its services in a more accountable and cost-effective fashion. Numerous organizational models of health care delivery systems aim to take advantage of economies of scale and integration. Many provide great opportunities to improve the health of individuals and of populations by better coordination of all aspects of medical care, and by assessing and responding to each individual's health risks. The need for connection between patient and a designated clinician remains strong, whatever the organizational structure of care delivery. In one study of patients receiving primary care among 13 practices, the most important determinant of whether a patient received appropriate preventive health measures was whether they were connected to a specific clinician [",
"    <a class=\"abstract\" href=\"UTD.htm?11/58/12200/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinicians must understand the \"systems\" in which and with which they practice medicine; practice in ways that demonstrate accountability for both the quality and the cost of the care they provide; and teach their patients how to use these systems effectively (",
"    <a class=\"graphic graphic_table graphicRef53207 \" href=\"UTD.htm?4/50/4907\">",
"     table 1",
"    </a>",
"    ). These three essential tasks are new competencies for clinicians. Clinicians have been slow to recognize the importance of understanding the structures, forces, incentives, and dynamic equilibria of the organizations in which they work. Systems thinking is central to the provision of high-quality care by large networks of providers. It involves philosophical appreciation that clinicians do not work alone for their patients, but rather on teams. It also requires procedural knowledge of \"how to get things done in this system\" and a capacity to collaborate with other stakeholders to bring about systems change where there are impediments to effective care.",
"   </p>",
"   <p>",
"    Effective systems thinking about medical care requires understanding the human, technological, and financial resources available within the system and an ethic surrounding resource distribution. Inherent in ethical systems of health care delivery is accountability both for the quality of the care delivered to individuals and for the cost of the care, assuring appropriate distribution of resources to all persons within the population served by the system. Any system is only as strong as its weakest component (technological, informational, financial, or human). Hence, good systems thinking also appreciates that the functioning and the outputs of the system must be continuously monitored and improved.",
"   </p>",
"   <p>",
"    Success in working in a medical care systems environment is complex. Clinicians join allied health providers (eg, nurses, clinician assistants, occupational and physical therapists, social workers, case managers, medical assistants, clinical support staff) and administrators on teams to assure that services are tailored to meet individual health care needs effectively and efficiently. This requires that everyone on the team appreciates each others' roles, abilities, and limitations, that everyone appreciates the extent of resources available to care for the patient, and that good mechanisms of communication effectively link team members. Good communications are enhanced when team members create real professional relationships that extend well beyond the exchange of order forms and consultation reports. The size and complexity of teams will vary with the needs of different patient populations and practice sites. Some may be \"virtual teams,\" connected electronically. We suspect that even on these teams, effectiveness and accountability is greatly enhanced when personal relationships lie behind the electronic exchanges.",
"   </p>",
"   <p>",
"    Responsible stewardship for health care resources in large health care delivery systems is not simply a matter of producing services at the least cost. Stewardship requires that human relationships be highly valued in all choices. It is within individual human relationships that patients can feel sufficient safety and trust to disclose their fears, symptoms, concerns, and preferences about their health. Creating these relationships, wherein patients feel heard, acknowledged, and understood, can be healing in itself. Furthermore, individual relationships foster professional satisfaction and pride for members of the health care team. All relationships matter, including clinician-patient, patient-unit secretary, primary care clinician-subspecialty consultant, patient-case manager, etc. A substantial portion of a patient's confidence in",
"    <span class=\"nowrap\">",
"     his/her",
"    </span>",
"    clinician will depend upon the clinician's skill and capacity to access and unfold the best aspects of the system for the patient.",
"   </p>",
"   <p>",
"    The trust forged in the initial clinician-patient relationship is often the key to a patient's willingness to participate in, and benefit from, care provided by members of a clinical team other than the clinician. Willingness to forego unnecessary and costly medical services is only present within a trusting clinician-patient relationship. In the final analysis, all systems of care are founded upon the capacity of the clinician to establish and sustain an effective relationship, first created in the context of a clinical visit.",
"   </p>",
"   <p>",
"    The clinician has numerous tasks during the patient visit (",
"    <a class=\"graphic graphic_table graphicRef51924 \" href=\"UTD.htm?30/25/31131\">",
"     table 2",
"    </a>",
"    ). This extensive work needs to be accomplished with every patient but fortunately not on every visit. The abstract list comes to life when it is appreciated as the work performed in a skillfully guided conversation, or series of conversations, between two people within a professional relationship. It is colored by the feelings and life experiences of both parties [",
"    <a class=\"abstract\" href=\"UTD.htm?11/58/12200/abstract/5\">",
"     5",
"    </a>",
"    ]. The methods applied must be tailored to the situation at hand, differing somewhat in the emergency department, consultant's office, and primary care office. In all settings, however, there are some consistent truths about medical encounters: all people are anxious to some extent when they come to see a clinician; all people desire and deserve to be treated with respect; all people want to be heard and understood by their clinicians; and almost all people expect to be professionally touched by their clinicians. This topic will review the knowledge, skills, and values needed to do this work well, for the satisfaction of the patient and the clinician.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     FUNCTIONS OF THE MEDICAL INTERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three functions of the medical interview have been identified (",
"    <a class=\"graphic graphic_table graphicRef65802 \" href=\"UTD.htm?15/21/15708\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/58/12200/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Data gathering",
"     </li>",
"     <li>",
"      Relationship building",
"     </li>",
"     <li>",
"      Patient education",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The three functions of the interview are interwoven throughout the dialogue of the clinician and patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Data gathering",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data gathering enables the clinician to establish a diagnosis or recommend further diagnostic procedures, suggest courses of treatment, and predict the nature of the illness. The tasks of this function are to:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acquire the appropriate knowledge base of diseases and disorders",
"     </li>",
"     <li>",
"      Acquire the knowledge base of psychosocial issues that contribute to the patient's illness behavior",
"     </li>",
"     <li>",
"      Bring the data that have been elicited into focus",
"     </li>",
"     <li>",
"      Generate and test multiple hypotheses during the course of the interview",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The verbal skills that facilitate accomplishing these tasks include asking open-ended questions (and waiting for the answers); active listening; making facilitative utterances (\"uh-huh, tell me more&hellip; yes&hellip; go on&hellip;\"); making orienting remarks (\"I will ask you about x, and then we will do y&hellip;\"); asking focusing questions when needed (\"Where was the pain? What made it worse?\"); eliciting and prioritizing the patient's agenda for the visit (\"What should we be certain to get done today?\"); checking for understanding; and summarizing what the clinician has heard (\"Let me be sure I have this right. You felt fine until you started shoveling snow, then you felt dizzy and thought you might faint,\" etc.) (",
"    <a class=\"graphic graphic_table graphicRef76848 \" href=\"UTD.htm?12/21/12636\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The nonverbal skills that facilitate good data collection start with \"clearing the clinician's mental and physical slate\" before entering the room with the patient. Important and often neglected nonverbal skills also include being aware of and consciously shaping how the clinician's appearance, body language, voice qualities (eg, tone, volume, pace), and the spatial arrangements of furniture and people in the room affect the interactions (",
"    <a class=\"graphic graphic_table graphicRef50644 \" href=\"UTD.htm?12/39/12924\">",
"     table 5",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Relationship building",
"    </span>",
"    &nbsp;&mdash;&nbsp;Relationship building seeks to ensure the patient's willingness to provide diagnostic and other important information, to relieve the patient's physical and psychosocial distress, to ensure the patient's willingness to accept the treatment plan or a process of negotiation, and to ensure both the patient's and clinician's satisfaction with work well-done. The tasks of this function are to:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Define the nature of the relationship",
"     </li>",
"     <li>",
"      Communicate professional expertise",
"     </li>",
"     <li>",
"      Communicate interest, respect, support, and empathy",
"     </li>",
"     <li>",
"      Recognize and resolve various relational barriers to",
"      <span class=\"nowrap\">",
"       patient/clinician",
"      </span>",
"      communication",
"     </li>",
"     <li>",
"      Elicit the patient's perspective",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The skills of effective relationship building are both verbal and nonverbal. The power and importance of nonverbal communication cannot be overstated. Consider, for example, the effect of nonverbal empathy when the clinician gently touches the shoulder of the newly widowed woman. All behavior is communication. Patients are reading nonverbal messages from clinicians consciously or unconsciously throughout each visit [",
"    <a class=\"abstract\" href=\"UTD.htm?11/58/12200/abstract/8\">",
"     8",
"    </a>",
"    ]. Does the clinician lean towards or away from the patient? Is there appropriate eye contact and head nodding to indicate listening? The clinician and patient assess whether the unspoken messages match the words. When they match, the veracity of the words is likely. A mismatch suggests need for some explicit checking (eg, patient says \"OK, I'll fill the prescription\" but looks absently out the window). The skillful clinician is consciously monitoring and controlling",
"    <span class=\"nowrap\">",
"     his/her",
"    </span>",
"    own nonverbal messages to the patient and is reading the nonverbal communication from the patient.",
"   </p>",
"   <p>",
"    The skillful clinician is also evaluating",
"    <span class=\"nowrap\">",
"     his/her",
"    </span>",
"    own thoughts and emotions and how these affect verbal and nonverbal responses to the patient and even influence clinical judgment. Is a growing sense of irritation in the clinician during an interview related to actions of the patient, or unrelated issues (eg, that second cup of coffee, air conditioning problems, or a disagreement at home the previous night?). Awareness of the effects of our own mental processes on our relationships with patients is often referred to as \"mindful practice\" and has been described as \"cultivation of the observing self in the midst of the complexity and chaos of everyday work\" [",
"    <a class=\"abstract\" href=\"UTD.htm?11/58/12200/abstract/9\">",
"     9",
"    </a>",
"    ]. Through mindful practice, clinicians improve their attention and ability to sense subtleties, reduce bias and premature categorization, and enhance openness to new ideas and actions.",
"   </p>",
"   <p>",
"    The appropriate use of language is also a crucial aspect of relationship building. Both what is said and how it is said are important. Verbal relationship building skills include statements of partnership, empathy, apology, respect, legitimation, and support (PEARLS) (",
"    <a class=\"graphic graphic_table graphicRef64050 \" href=\"UTD.htm?40/60/41931\">",
"     table 6",
"    </a>",
"    ). Empathy is most easily conveyed by the use of reflection. Communication of understanding of emotion through reflective statements such as \"that was tough for you\" or even \"gosh!\" can deepen the therapeutic relationship and improve patient satisfaction [",
"    <a class=\"abstract\" href=\"UTD.htm?11/58/12200/abstract/10\">",
"     10",
"    </a>",
"    ]. Legitimation refers to voicing acceptance or validation of the emotions or reactions of the patient [",
"    <a class=\"abstract\" href=\"UTD.htm?11/58/12200/abstract/11\">",
"     11",
"    </a>",
"    ]. A simple \"I'd be upset by that too\" can be reassuring to an anxious or angry patient and turn a difficult encounter into a productive one.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Patient education",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patient education seeks to ensure the patient's understanding of the illness, to suggest diagnostic procedures and treatment possibilities, to foster consensus between clinician and patient, and to create a firm foundation for informed consent, improved coping mechanisms, and the promotion of healthy lifestyle change. Providing appropriate patient education to foster consensus and allow full informed consent is one way that clinicians show respect for their patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/58/12200/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The tasks of this function are to:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Determine the areas of differences (potential conflict) between the clinician and patient, and promote negotiation to resolve the differences",
"     </li>",
"     <li>",
"      Communicate about the diagnostic significance of the problem(s)",
"     </li>",
"     <li>",
"      Recommend the appropriate diagnostic procedures and treatment, including appropriate preventive measures and lifestyle changes",
"     </li>",
"     <li>",
"      Enhance coping ability by understanding and working with the social and psychosocial consequences of the disease and treatment",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The skills of patient education involve asking questions to discover what the patient knows about the illness, how",
"    <span class=\"nowrap\">",
"     s/he",
"    </span>",
"    feels about it, what",
"    <span class=\"nowrap\">",
"     s/he",
"    </span>",
"    believes about it, what meanings",
"    <span class=\"nowrap\">",
"     s/he",
"    </span>",
"    attaches to it, and what",
"    <span class=\"nowrap\">",
"     s/he",
"    </span>",
"    expects to happen because of the illness",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    its treatment. The two keys to successful patient education are the use of comprehensible language and avoidance of \"too much, too soon, too fast.\"",
"   </p>",
"   <p>",
"    The skillful clinician's questions probe the patient's \"need to know\" in each of these areas.",
"    <span class=\"nowrap\">",
"     S/he",
"    </span>",
"    then calibrates responses in both content and tone to exactly what the patient wants to know. If the clinician senses resistance to learning about something that is important from",
"    <span class=\"nowrap\">",
"     her/his",
"    </span>",
"    perspective, this resistance must be explored. Invariably, such an exploration will uncover important patient concerns, fears, prior adverse experience, or serious misunderstanding of what the clinician is saying. In summary, the content of effective patient education rests upon the clinician's knowledge, but that is not enough. Its implementation requires an open, trusting clinician-patient relationship. Patient education is best accomplished in a true conversation between clinician and patient, not through a clinician monologue (",
"    <a class=\"graphic graphic_table graphicRef63604 \" href=\"UTD.htm?6/19/6461\">",
"     table 7",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     EFFECTIVE CLINICIAN STRATEGIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Four general categories of clinician behaviors lead to effective patient care (",
"    <a class=\"graphic graphic_table graphicRef54037 \" href=\"UTD.htm?0/52/844\">",
"     table 8",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/58/12200/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cognitive strategies (knowledge-related)",
"     </li>",
"     <li>",
"      Affective strategies (emotion-related)",
"     </li>",
"     <li>",
"      Behavioral change strategies",
"     </li>",
"     <li>",
"      Social strategies (invoking group mechanisms beyond the individual)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Cognitive strategies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effective clinician negotiates patient priorities and expectations explicitly at the beginning of the relationship, as well as at subsequent critical junctures of decision making.",
"    <span class=\"nowrap\">",
"     S/he",
"    </span>",
"    gives a complete explanation of the patient's condition and treatment options, encouraging questions that expand the patient's understanding. Through this dialogue, the clinician brings the patient to a \"decision crossroads\" at which",
"    <span class=\"nowrap\">",
"     s/he",
"    </span>",
"    is ready to make informed choices about treatment. The clinician also educates the patient about difficulties",
"    <span class=\"nowrap\">",
"     s/he",
"    </span>",
"    might have with",
"    <span class=\"nowrap\">",
"     her/his",
"    </span>",
"    condition or its management, and offers a prognosis of what may be expected to happen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Affective strategies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effective clinician conveys",
"    <span class=\"nowrap\">",
"     his/her",
"    </span>",
"    genuine empathy for the patient in many ways. These include facilitating full expression of the emotional content of the patient's experience; providing encouragement and reassurance when needed and suitable; touching the patient appropriately; and taking actions that sustain hope. The clinician also facilitates patient self-forgiveness, in anticipation of or after failure in the face of a challenge.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Behavioral change strategies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effective clinician discovers a patient's readiness to change any particular unhealthy behavior. One group has described stages of behavior change as precontemplation, contemplation, preparation, action, and then either maintenance of the new, healthier behavior or relapse into the old, unhealthy behavior [",
"    <a class=\"abstract\" href=\"UTD.htm?11/58/12200/abstract/15\">",
"     15",
"    </a>",
"    ]. Understanding the patient's readiness to change and then matching the clinician's educational strategy to that stage is key to successful change efforts.",
"   </p>",
"   <p>",
"    Patients in precontemplation need to hear clearly from the clinician that the behavior is likely to have unhealthy consequences. To produce an environment in which the patient will be willing to discuss real behavior change, the clinician needs to acknowledge the struggles involved in changing behaviors and accept the ambivalence most people have about changing behaviors, including those that are obviously destructive.",
"   </p>",
"   <p>",
"    Patients in contemplation need help from the clinician to explore the pros and cons of continuing versus stopping the unhealthy behavior. Exploring the pros of the unhealthy behavior (eg \"What do you like about smoking?\") as an initial step can often reduce defensiveness and open conversation. Reviewing past attempts at change may be helpful. Emphasis should be placed on past successes (\"You were able to quit for an entire week!\"), leading to increased self-efficacy and hope.",
"   </p>",
"   <p>",
"    Patients in preparation may need the clinician's help in planning a specific behavior change strategy, and patients in action may benefit from the prescription of specific treatments that can support the change (eg, alternative nicotine delivery systems to aid in smoking cessation). The clinician must explain clearly the goals of any specific treatment and the means of achieving them, emphasizing the benefits and necessity of the patient's active participation in the program of care.",
"    <span class=\"nowrap\">",
"     S/he",
"    </span>",
"    provides regular, positive feedback for patient adherence to the program, and when needed, suggests alternative courses if the original path proves impossible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Social strategies",
"    </span>",
"    &nbsp;&mdash;&nbsp;In all of these activities, when appropriate, the effective clinician employs social group strategies to improve health outcomes. These include obtaining permission from the patient to inform and involve family members in the patient's care, as well as collaboration with appropriate community organizations. The clinician explicitly creates coherent teamwork for patient care, sharing information about",
"    <span class=\"nowrap\">",
"     his/her",
"    </span>",
"    own care activities with other members of the health professions team.",
"   </p>",
"   <p>",
"    The first decade of the 21",
"    <sup>",
"     st",
"    </sup>",
"    century has seen social strategies to improve health and healthcare adopted as a new &ldquo;way of doing business&rdquo; by many leading academic and community hospitals. Referred to as &ldquo;patient- and family-centered care,&rdquo; this approach brings thoughtful patients and family members into the administrative decision-making practices of hospitals and office practices. Patients and family members offer their insights into how health care delivery can be made more &ldquo;user-friendly&rdquo; and efficient. &nbsp;The four core concepts of patient- and family-centered care are [",
"    <a class=\"abstract\" href=\"UTD.htm?11/58/12200/abstract/16\">",
"     16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dignity and Respect &mdash; Listen to and honor patient and family perspectives and choices",
"     </li>",
"     <li>",
"      Information Sharing &mdash; Communicate and share complete information with patients and families in ways that are affirming and useful",
"     </li>",
"     <li>",
"      Participation &mdash; Patients and families are encouraged and supported in participating in care and decision making at the level they choose",
"     </li>",
"     <li>",
"      Collaboration &mdash; Patients, families, and health care practitioners and leaders collaborate in policy and program development, implementation and evaluation, in facility design, and in professional education as well as in delivery of care",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The potential for patient- and family-centered care to improve patient safety and satisfaction, the cost of care, and provider satisfaction is substantial and is becoming an important research topic. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DESIRABLE CLINICIAN BEHAVIORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients' descriptions of desirable clinician behaviors can be grouped into three major dimensions (",
"    <a class=\"graphic graphic_table graphicRef52737 \" href=\"UTD.htm?0/48/780\">",
"     table 9",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/58/12200/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Behaviors expected of clinicians because they are professionals",
"     </li>",
"     <li>",
"      Clinician behaviors understood by patients to be respectful",
"     </li>",
"     <li>",
"      Clinician behaviors understood by patients to be supportive",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients expect clinicians to groom and dress appropriately, minimize frustrations from prior visits with other patients that carry over into subsequent visits, be punctual, treat them like an equal, engage in the courteous behaviors expected among equals (eg, shaking hands, calling patients by the names they prefer, sitting down with them, etc.), and to engage in activities that establish a relaxed atmosphere in spite of patients' anxiety. These help to get the visit off to the right start.",
"   </p>",
"   <p>",
"    Clinicians should prepare in advance for the visit, minimize interruptions during the visit, listen actively and seek to understand fully the patient's illness history, explain elements of the physical examination as it proceeds, take all the patient's complaints seriously even if they are not medically plausible, and express concern for the effects of the illness in the patient's daily life. Critical professional behaviors when talking about a diagnosis and its possible therapy include clear and complete explanations of the problem and treatment, and the clinician's knowing",
"    <span class=\"nowrap\">",
"     his/her",
"    </span>",
"    own limitations, referring when necessary for consultation.",
"   </p>",
"   <p>",
"    Respectful clinician behaviors when talking about a problem and its treatment include involving the patient in making treatment choices and being honest under all circumstances. Supportive actions on the part of the clinician include taking time to talk no matter how busy and encouraging patient and family questions. In follow-up activities, the clinician provides the patient with ready access to care including cross-coverage when",
"    <span class=\"nowrap\">",
"     s/he",
"    </span>",
"    is away, and follows through on all promises made to the patient. The respectful clinician involves the patient in management and is conscious of the financial implications of the patient's illness. Finally, the supportive clinician checks on the patient at home (eg, with a telephone call), specifically on what the patient has agreed to do, however challenging.",
"   </p>",
"   <p>",
"    The overarching task for clinicians is to appreciate and act upon patient preferences for better integrated conversations in medical visits and for greater attention to psychosocial issues and affect-loaded problems. The ultimate challenge is not a cognitive one, but a behavioral one: to stay in close touch with the clinician's own humanity, no matter how harried the day, and to connect with the patient.",
"   </p>",
"   <p>",
"    This behavioral task of making a good connection with each patient must be realistically considered within the context of time-limited office and hospital visits. Research demonstrates that expressly attending to affect-loaded problems can in fact improve efficiency as well as improve patient and provider satisfaction [",
"    <a class=\"abstract\" href=\"UTD.htm?11/58/12200/abstract/19\">",
"     19",
"    </a>",
"    ]. Approaches that have been proven to save time include allowing patients to offer and finish their opening statements, negotiating a consensually prioritized agenda for the visit, responding to patients' reactions and concerns with empathy, and offering patients orientation to the events of the visit [",
"    <a class=\"abstract\" href=\"UTD.htm?11/58/12200/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The \"Four Habits Approach\" to clinical communication provides a useful and well-validated summary of clinician behaviors during a medical visit that have proven to be effective for both the patient and clinician (",
"    <a class=\"graphic graphic_table graphicRef69929 \" href=\"UTD.htm?4/21/4446\">",
"     table 10",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/58/12200/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     PROFESSIONAL VALUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dr. Francis W. Peabody's often-quoted address on \"The Care of the Patient\" speaks eloquently to the value of clinicians' respect for humanity and the value of the clinician-patient relationship to treatment itself. \"The significance of the intimate personal relationship between clinician and patient cannot be too strongly emphasized, for in an extraordinarily large number of cases both the diagnosis and the treatment are directly dependent on it. One of the essential qualities of the clinician is interest in humanity, for the secret of the care of the patient is caring for the patient\" [",
"    <a class=\"abstract\" href=\"UTD.htm?11/58/12200/abstract/22\">",
"     22",
"    </a>",
"    ]. Carl Rogers studied and taught about the beneficial outcomes for learning and for health that result from approaching a",
"    <span class=\"nowrap\">",
"     learner/patient",
"    </span>",
"    with unconditional positive regard [",
"    <a class=\"abstract\" href=\"UTD.htm?11/58/12200/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The American Board of Internal Medicine has placed increasing importance on humanistic qualities as it considers candidates for its examination. It requires program directors to evaluate residents' personal integrity, and their respect and compassion for patients. The Pew-Fetzer Task Force on Advancing Psychosocial Health Education carefully considered areas of knowledge, skills, and values that support effective patient-practitioner relationships (",
"    <a class=\"graphic graphic_table graphicRef71179 \" href=\"UTD.htm?25/48/26380\">",
"     table 11",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/58/12200/abstract/24\">",
"     24",
"    </a>",
"    ]. They emphasize the following values: importance of self-awareness, self-care, and self-growth; appreciation of the patient's life story and the meaning of the health-illness condition; respect for the patient's dignity, uniqueness, and integrity (mind-body-spirit unity); respect for self-determination; respect for a person's own power and self-healing processes; and the importance of being open and nonjudgmental.",
"   </p>",
"   <p>",
"    In addition to the above observations, we would highlight the importance of ascribing value to several other features of clinician-patient interactions:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Clinical curiosity",
"     </li>",
"     <li>",
"      Attention to decision-making preferences",
"     </li>",
"     <li>",
"      Attention to cultural issues",
"     </li>",
"     <li>",
"      Attention to accountability",
"     </li>",
"     <li>",
"      Attention to professionalism",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Clinical curiosity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Respectful curiosity about the person in front of you and about medicine brings energy, vitality, salience, and meaningfulness to medical visits. It is healthy for the encounter, and critically important to the sustenance of the clinician's dedication to",
"    <span class=\"nowrap\">",
"     his/her",
"    </span>",
"    work.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Explicit attention to decision-making preferences",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients vary in the degree to which they want to share in medical decision-making. Many older patients prefer the clinician to hold most of the authority, while younger patients are apt to want to play an active role in shaping diagnostic and therapeutic plans [",
"    <a class=\"abstract\" href=\"UTD.htm?11/58/12200/abstract/19\">",
"     19",
"    </a>",
"    ]. No rules hold, however, so the operative value needs to be one of respecting each individual's preference for the extent to which decision-making is shared, and the operative behavior must be to check explicitly about that preference.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Attention to cultural issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;We have alluded to the importance of knowledge about cultural differences between patients and clinicians. For this knowledge to be of real use, to effect medical outcomes of care, the clinician must move beyond cognition of cultural differences to truly valuing and respecting the beliefs of each patient to whom",
"    <span class=\"nowrap\">",
"     s/he",
"    </span>",
"    provides care. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/61/24537?source=see_link\">",
"     \"Cross-cultural care and communication\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Attention to accountability",
"    </span>",
"    &nbsp;&mdash;&nbsp;Much of medical training inculcates clinicians with a strong sense of responsibility. \"The buck stops here\" is a feeling well known by every intern. While this can greatly benefit patients when the clinician is personally executing every aspect of care, that is now rarely the case. It is not an effective point of view when the clinician is part of a team. Clinician arrogance about \"who knows best\" is unfortunately another well-known phenomenon. The clinician must hold responsibility for",
"    <span class=\"nowrap\">",
"     his/her",
"    </span>",
"    part in the team's work, but must also appreciate each team member's role and skills. All team members are responsible for respectful collaboration in the work and participation in a system that monitors outcomes of care and provides clear and timely feedback about each team member's performance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Attention to professionalism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Effective interactions between each clinician and patient depend, at their core, on mutual trust. Survey data show that the levels of trust and respect that were formerly extended to the profession of medicine have substantially eroded over the past 40 years [",
"    <a class=\"abstract\" href=\"UTD.htm?11/58/12200/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. Societal skepticism about the trustworthiness of medicine has many legitimate sources and is a cause for concern.",
"   </p>",
"   <p>",
"    What can we do to restore the public's trust in our chosen profession? While there is no straightforward solution, we can begin by being aware of this challenging situation and mindful of the foundational values that can guide our behavior with each patient we approach (",
"    <a class=\"graphic graphic_figure graphicRef81986 \" href=\"UTD.htm?27/46/28398\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We must learn to use and balance our values when navigating particularly difficult situations with patients (eg, breaking bad news, withholding an unnecessary and costly",
"      <span class=\"nowrap\">",
"       technology/test).",
"      </span>",
"     </li>",
"     <li>",
"      We must openly reveal to our patients (and students) the basis for the professional judgments we are making.",
"     </li>",
"     <li>",
"      We must actively take patients' preferences into consideration, and be prepared to change our opinions when new information becomes available, including the basis for patients' opinions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Only by making this 'juggling act' explicit will we regain trust and avoid perpetuating some of the most damaging situations of all, ones in which we contribute to racial, ethnic, and other disparities through our implicit processes of stereotyping and misperceptions [",
"    <a class=\"abstract\" href=\"UTD.htm?11/58/12200/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     CONTINUOUS LEARNING",
"    </span>",
"    &nbsp;&mdash;&nbsp;As Hippocrates observed, the art is long and life is short. No one of us truly \"masters\" skillful approaches to all patients in all situations. We mature, grow in our professional experience, and hope to improve our capacity for this most fundamental of clinical tasks. Several additional techniques can support our continued learning in this domain (",
"    <a class=\"graphic graphic_table graphicRef70370 \" href=\"UTD.htm?32/36/33355\">",
"     table 12",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/58/12200/abstract/28-30\">",
"     28-30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are two other special resources available to help us enhance our approaches to patients. The American Academy on Communication in Healthcare (formerly the American Academy on Physician and Patient) is an organization of health care providers committed to enriching the practice and teaching of medicine by improving the clinician-patient relationship through educational programs, research, scholarly publications, and teaching resources [",
"    <a class=\"abstract\" href=\"UTD.htm?11/58/12200/abstract/31-33\">",
"     31-33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A second valuable resource is the American Balint Society [",
"    <a class=\"abstract\" href=\"UTD.htm?11/58/12200/abstract/34\">",
"     34",
"    </a>",
"    ], which continues the work of Dr. George Balint and his wife, Enid. The Balints began their work in England during the first half of the 20",
"    <sup>",
"     th",
"    </sup>",
"    century. They developed discussion groups (now called Balint Groups) wherein clinicians present their patients' stories to each other (maintaining appropriate patient confidentiality) and then discuss aspects of the clinician-patient interactions that seem meaningful or puzzling. The goals of the discussion are increased understanding of the patient's perception of",
"    <span class=\"nowrap\">",
"     his/her",
"    </span>",
"    situation and increased personal awareness for the clinician, the consequences of which are a better understanding of how to work effectively with the patient [",
"    <a class=\"abstract\" href=\"UTD.htm?11/58/12200/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We owe it to our patients and ourselves to continue to reflect and improve our interactions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clinicians must recognize the importance of managing the care of patients within a system so as to maximize quality of the care delivered to their patients. A substantial portion of a patient's confidence in",
"      <span class=\"nowrap\">",
"       his/her",
"      </span>",
"      clinician will depend upon the clinician's skill and capacity to access and unfold the best aspects of the system for the patient. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The medical interview has three functions: data gathering, relationship building, and patient education. Nonverbal communication is an important component of the interview. Attention to one's mental processes during an interview (mindful practice) improves understanding of the patient, reduces bias, and can enhance clinical judgment. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Functions of the medical interview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Effective patient care involves four strategic elements that can be categorized as cognitive, affective, behavioral, and social. Cognitive strategies encourage dialog that expands patients' understanding of their condition and allows informed medical decisions. Affective strategies convey empathy and facilitate patient self-forgiveness. Behavioral change strategies target a patient's readiness to accept help or treatment. Social strategies involve the patient's family or community in collaborating with the patient to improve health outcomes. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Effective clinician strategies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The \"Four Habits Approach\" to clinical communication provides a useful and well-validated summary of clinician behaviors during a medical visit that have proven to be effective for both the patient and clinician (",
"      <a class=\"graphic graphic_table graphicRef69929 \" href=\"UTD.htm?4/21/4446\">",
"       table 10",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Desirable clinician behaviors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The patient-practitioner relationship is enhanced by a number of clinician attributes including: respect for patient dignity and self-determination, clinical curiosity, attention to decision-making preferences and cultural issues, accountability, and professionalism. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Professional values'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/58/12200/abstract/1\">",
"      Fletcher RH, Fletcher SW. Evidence-based approach to the medical literature. J Gen Intern Med 1997; 12 Suppl 2:S5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/58/12200/abstract/2\">",
"      Levinson W, Pizzo PA. Patient-physician communication: it's about time. JAMA 2011; 305:1802.",
"     </a>",
"    </li>",
"    <li>",
"     Forster, EM. Howard's End, Signet, 1992.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/58/12200/abstract/4\">",
"      Atlas SJ, Grant RW, Ferris TG, et al. Patient-physician connectedness and quality of primary care. Ann Intern Med 2009; 150:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/58/12200/abstract/5\">",
"      Novack DH, Suchman AL, Clark W, et al. Calibrating the physician. Personal awareness and effective patient care. Working Group on Promoting Physician Personal Awareness, American Academy on Physician and Patient. JAMA 1997; 278:502.",
"     </a>",
"    </li>",
"    <li>",
"     Cohen-Cole SA. The Medical Interview: The Three-Function Approach, Mosby Year Book, St. Louis 1991.",
"    </li>",
"    <li>",
"     Lazare A, Putnam SM, Lipkin M Jr. Three functions of the medical interview. In: The Medical Interview: Clinical Care, Education, and Research, Lipkin M Jr, Putnam SM, Lazare A, et al (Eds), Springer-Verlag, New York 1995. p.6.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/58/12200/abstract/8\">",
"      Roter DL, Frankel RM, Hall JA, Sluyter D. The expression of emotion through nonverbal behavior in medical visits. Mechanisms and outcomes. J Gen Intern Med 2006; 21 Suppl 1:S28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/58/12200/abstract/9\">",
"      Epstein RM, Siegel DJ, Silberman J. Self-monitoring in clinical practice: a challenge for medical educators. J Contin Educ Health Prof 2008; 28:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/58/12200/abstract/10\">",
"      Takemura YC, Atsumi R, Tsuda T. Which medical interview behaviors are associated with patient satisfaction? Fam Med 2008; 40:253.",
"     </a>",
"    </li>",
"    <li>",
"     Cohen-Cole SA. The \"difficult\" medical patient. In: Clinical Methods: The History, Physical, and Laboratory, Walker HK, Hall DW, Hurst HW (Eds), Butterworth Publishers, 1990.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/58/12200/abstract/12\">",
"      Beach MC, Roter DL, Wang NY, et al. Are physicians' attitudes of respect accurately perceived by patients and associated with more positive communication behaviors? Patient Educ Couns 2006; 62:347.",
"     </a>",
"    </li>",
"    <li>",
"     Novack DH. Therapeutic aspects of the clinical encounter. In: The Medical Interview: Clinical Care, Education, and Research, Lipkin M Jr, Putnam SM, Lazare A, et al (Eds), Springer-Verlag, New York 1995. p.32.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/58/12200/abstract/14\">",
"      Inui TS. Establishing the doctor-patient relationship: science, art, or competence? Schweiz Med Wochenschr 1998; 128:225.",
"     </a>",
"    </li>",
"    <li>",
"     Prochaska JO, Norcross JC. Changing for Good, Avon Books, 1995.",
"    </li>",
"    <li>",
"     Institute for Patient- and Family-Centered Care. Available at: file://www.ipfcc.org/ (Accessed on October 24, 2011).",
"    </li>",
"    <li>",
"     American Board of Internal Medicine: Guide to awareness and evaluation of humanistic qualities in the internist, 1992-1995, American Board of Internal Medicine, Philadelphia 1992. p.1.",
"    </li>",
"    <li>",
"     Carter WB, Inui TS. Humanistic behavior of physician as rated by patients. Technical report submitted to the American Board of Internal Medicine, Philadelphia 1992.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/58/12200/abstract/19\">",
"      Roter DL, Stewart M, Putnam SM, et al. Communication patterns of primary care physicians. JAMA 1997; 277:350.",
"     </a>",
"    </li>",
"    <li>",
"     Gordon GH. Managed Care. In: Behavioral Medicine in Primary Care - A Practical Guide, Feldman MD, Christensen JF (Eds), Appleton &amp; Lange, Stamford, CT 1997. p.47.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/58/12200/abstract/21\">",
"      Frankel RM, Stein T. Getting the most out of the clinical encounter: the four habits model. J Med Pract Manage 2001; 16:184.",
"     </a>",
"    </li>",
"    <li>",
"     Peabody FW. The Care of the Patient, an address to Harvard Medical students, 1927.",
"    </li>",
"    <li>",
"     Rogers CS. Freedom to Learn for the 80s, Charles E. Merrill Publishing Company, Columbus 1983.",
"    </li>",
"    <li>",
"     Tresoloni CP, the Pew-Fetzer Task Force on Advancing Psychosocial Health Education. Health Professions Education and Relationship-Centered Care, Pew Health Professions Commission, San Francisco 1994. p.30.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/58/12200/abstract/25\">",
"      Schlesinger M. A loss of faith: the sources of reduced political legitimacy for the American medical profession. Milbank Q 2002; 80:185.",
"     </a>",
"    </li>",
"    <li>",
"     Inui TS. A flag in the wind: Educating for professionalism in medicine. 2003 Association of American Medical Colleges 2003. Available at: www.aamc.org/Publications (Accessed on August 24, 2009).",
"    </li>",
"    <li>",
"     Smedley BD, Stith AY, Nelson AR, the Institute of Medicine Committee on Understanding and Eliminating Racial and Ethnic Disparities in Health Care. Unequal Treatment: Confronting Racial and Ethnic Disparities in Health Care, National Academy Press, Washington, D.C. 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/58/12200/abstract/28\">",
"      Branch WT, Suchman A. Meaningful experiences in medicine. Am J Med 1990; 88:56.",
"     </a>",
"    </li>",
"    <li>",
"     Coles R. The Call of Stories: Teaching and the Moral Imagination, Houghton Mifflin Company, Boston 1989.",
"    </li>",
"    <li>",
"     On Doctoring: Stories Poems Essays (doctor's favorite stories), Reynolds R, Stone J (Eds), Simon &amp; Schuster, New York 1991.",
"    </li>",
"    <li>",
"     American Academy on Communication in Healthcare. www.aachonline.org (Accessed on January 19, 2007).",
"    </li>",
"    <li>",
"     The Medical Interview: Clinical Care, Education, and Research, Lipkin M Jr, Putnam SM, Lazare A, et al (Eds), Springer-Verlag, New York 1995.",
"    </li>",
"    <li>",
"     Novack D, Clark W, Salzow R, et al. An interactive learning resource for healthcare communication. American Academy on Communication in Healthcare, St. Louis 2006. Available at: www.aachonline.org (Accessed on January 19, 2007).",
"    </li>",
"    <li>",
"     American Balint Society. Laurel Milberg, President. Forbes Family Practice Residency, 2566 Haymaker Road, Monroeville, PA 15146. phone: 412-858-2769.",
"    </li>",
"    <li>",
"     Balint M. The Doctor, His Patient, and the Illness (Revised Edition), International Universities Press Inc, Madison, Connecticut 1964.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2754 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-183.1.191.153-340D2F8564-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_58_12200=[""].join("\n");
var outline_f11_58_12200=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      FUNCTIONS OF THE MEDICAL INTERVIEW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Data gathering",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Relationship building",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Patient education",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      EFFECTIVE CLINICIAN STRATEGIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Cognitive strategies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Affective strategies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Behavioral change strategies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Social strategies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DESIRABLE CLINICIAN BEHAVIORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      PROFESSIONAL VALUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Clinical curiosity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Explicit attention to decision-making preferences",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Attention to cultural issues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Attention to accountability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Attention to professionalism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      CONTINUOUS LEARNING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/2754\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/2754|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/46/28398\" title=\"figure 1\">",
"      Staying centered on values",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/2754|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/50/4907\" title=\"table 1\">",
"      Essential clinician tasks",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/25/31131\" title=\"table 2\">",
"      Clinician tasks",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/21/15708\" title=\"table 3\">",
"      Functions of medical interview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/21/12636\" title=\"table 4\">",
"      Verbal skills pt interview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/39/12924\" title=\"table 5\">",
"      Nonverbal skills pt interview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/60/41931\" title=\"table 6\">",
"      Verbal relationship building",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/19/6461\" title=\"table 7\">",
"      Patient education skills",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/52/844\" title=\"table 8\">",
"      Behaviors that enhance outcome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/48/780\" title=\"table 9\">",
"      Desirable clinician behaviors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/21/4446\" title=\"table 10\">",
"      Four habits model",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/48/26380\" title=\"table 11\">",
"      Supports of pt relationship",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/36/33355\" title=\"table 12\">",
"      Improving our approach to pts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/61/24537?source=related_link\">",
"      Cross-cultural care and communication",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_58_12201="Subcorneal pustular dermatosis close view";
var content_f11_58_12201=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F71995&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F71995&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Subcorneal pustular dermatosis close view",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 576px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple flaccid pustules and areas of crusting are present on the skin. The largest lesion has a somewhat annular configuration.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_58_12201=[""].join("\n");
var outline_f11_58_12201=null;
var title_f11_58_12202="Ritonavir: Drug information";
var content_f11_58_12202=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ritonavir: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?5/35/5686?source=see_link\">",
"    see \"Ritonavir: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?6/9/6298?source=see_link\">",
"    see \"Ritonavir: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709403\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F218758\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Norvir&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F218759\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Norvir&reg;;",
"     </li>",
"     <li>",
"      Norvir&reg; SEC",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F218795\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antiretroviral Agent, Protease Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F218763\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Must be given in combination with other antiretroviral agents. Norvir&reg; tablets are",
"     <b>",
"      not",
"     </b>",
"     bioequivalent to Norvir&reg; capsules. Gastrointestinal side effects or paresthesias may be more common initially when patients are switching from the capsule to the tablet formulation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Treatment of HIV infection:",
"     </b>",
"     Manufacturer&rsquo;s labeling: Oral (",
"     <b>",
"      Note:",
"     </b>",
"     Not recommended as the primary protease inhibitor in any regimen [DHHS, 2013]): Initiate dose at 300 mg twice daily, then increase by 100 mg twice daily every 2-3 days to recommended dosage of 600 mg twice daily (maximum: 600 mg twice daily)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pharmacokinetic &ldquo;booster&rdquo; in combination with other protease inhibitors (unlabeled use):",
"     </b>",
"     Oral:100-400 mg daily in 1-2 divided doses (DHHS, 2013)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Recommended as the &ldquo;booster&rdquo; component in the following preferred regimens in treatment-naive patients: Atazanavir and tenofovir/emtricitabine, or darunavir and tenofovir/emtricitabine (DHHS, 2013). In patients without evidence of PI resistance, once-daily booster-dosing of 100 mg ritonavir may be preferred to 200 mg daily due to less gastrointestinal and metabolic adverse events. Refer to individual protease inhibitor monographs; specific dosage recommendations often require adjustment of both agents.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F218779\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?6/9/6298?source=see_link\">",
"      see \"Ritonavir: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Must be given in combination with other antiretroviral agents. Norvir&reg; tablets are",
"     <b>",
"      not",
"     </b>",
"     bioequivalent to Norvir&reg; capsules. Gastrointestinal side effects or paresthesias may be more common initially when patients are switching from the capsule to the tablet formulation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Treatment of HIV infection:",
"     </b>",
"     Manufacturer&rsquo;s labeling:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Infants &gt;1 month and Children: Oral: Initiate dose at  250 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose twice daily; titrate dose upward every 2-3 days by 50 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     twice daily to recommended dosage of 350-400 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose twice daily (maximum dose: 600 mg twice daily). If 400 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose twice daily is not tolerated, the highest tolerated dose may be used for maintenance therapy.",
"     <b>",
"      Note:",
"     </b>",
"     Oral solution should not be administered to neonates before a postmenstrual age (first day of mother&rsquo;s last period to birth plus the time elapsed after birth) &lt;44 weeks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Adolescents: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F218764\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F16361016\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment necessary.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F218765\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Mild-to-moderate impairment (Child-Pugh class A or B): No dosage adjustment necessary; however, ritonavir levels may be decreased in moderate impairment and patient response should be monitored.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Severe impairment (Child-Pugh class C): Not recommended (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F218733\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, soft gelatin, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Norvir&reg;: 100 mg [contains ethanol, polyoxyl 35 castor oil]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Norvir&reg;: 80 mg/mL (240 mL) [contains ethanol, polyoxyl 35 castor oil, propylene glycol; peppermint-caramel flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Norvir&reg;: 100 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F218718\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F218736\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer all formulations with food, per the manufacturer. DHHS guidelines recommend administering the tablets with food and administering capsules or oral solution with food, if possible, to improve tolerability (DHHS, 2013). Liquid formulations usually have an unpleasant taste. Consider mixing it with chocolate milk or a liquid nutritional supplement and taking within 60 minutes. Whenever possible, administer oral solution with calibrated dosing syringe. Shake solution well before use. Tablets should be swallowed whole; do not chew, break, or crush.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F218734\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of HIV infection; should always be used as part of a multidrug regimen",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F16360985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Used as a pharmacokinetic \"booster\" for other protease inhibitors",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F218803\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Ritonavir may be confused with Retrovir&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Norvir&reg; may be confused with Norvasc&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F218793\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Percentages as reported for combined experiences in both treatment-naive and experienced adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypercholesterolemia (&gt;240 mg/dL: 37% to 45%), triglycerides increased (&gt;800 mg/dL: 17% to 34%; &gt;1500 mg/dL: 1% to 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (26% to 30%), diarrhea (15% to 23%), vomiting (14% to 17%), taste perversion (7% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: GGT increased (5% to 20%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (10% to 15%), creatine phosphokinase increased (9% to 12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     2% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Vasodilation (2%), syncope (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (6% to 7%), fever (1% to 5%), dizziness (3% to 4%), insomnia (2% to 3%), somnolence (2% to 3%), depression (2%), anxiety (up to 2%), malaise (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (up to 4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Uric acid increased (up to 4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain (6% to 8%), anorexia (2% to 8%), dyspepsia (up to 6%), local throat irritation (2% to 3%), flatulence (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Transaminases increased (6% to 10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Paresthesia (3% to 7%), arthralgia (up to 2%), myalgia (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Pharyngitis (&le;1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis (2% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;2% (Limited to important or life-threatening): Abnormal vision. acute myeloblastic leukemia, adrenal cortex insufficiency, adrenal suppression, anaphylaxis, allergic reaction, amnesia, anemia, angioedema, aphasia, asthma, atrioventricular block (first, second, or third degree), bleeding increased (in patients with hemophilia A or B), bronchospasm, cachexia, cerebral ischemia, cerebral venous thrombosis, chest pain, cholestatic jaundice, coma, Cushing's syndrome, dehydration, dementia, depersonalization, diabetes mellitus, dyspnea, edema, esophageal ulcer, gastroenteritis, gastrointestinal hemorrhage, hallucinations, hepatic coma, hepatitis, hepatomegaly, hepatosplenomegaly, hyper-/hypotension, hypercholesteremia, hypothermia, hypoventilation, ileus, immune reconstitution syndrome, interstitial pneumonia, kidney failure, larynx edema, leukopenia, lymphadenopathy, lymphocytosis, manic reaction, MI, myeloproliferative disorder, neuropathy, orthostatic hypotension, palpitation, pancreatitis, paralysis, pseudomembranous colitis, QT prolongation, rectal hemorrhage, redistribution of body fat,right bundle branch block, seizure, skin melanoma, Stevens-Johnson syndrome, subdural hematoma, syncope, tachycardia, thrombocytopenia, tongue edema, torsade de pointes, toxic epidermal necrolysis, ulcerative colitis, urticaria, vasospasm",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F218739\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to ritonavir or any component of the formulation; concurrent alfuzosin, amiodarone, cisapride, dihydroergotamine, ergonovine, ergotamine, flecainide, lovastatin, methylergonovine, midazolam (oral), pimozide, propafenone, quinidine, sildenafil (when used for the treatment of pulmonary arterial hypertension [eg, Revatio&reg;]), simvastatin, St John&rsquo;s wort,  triazolam, and voriconazole (when ritonavir &ge;800 mg/day)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling: Additional contraindications (not in U.S. labeling): Concurrent use with rivaroxaban, voriconazole (regardless of ritonavir dose), salmeterol, vardenafil, bepridil, astemizole, or terfenadine",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F218722\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Protease inhibitors have been associated with a variety of hypersensitivity events (some severe), including rash, anaphylaxis (rare), angioedema, bronchospasm, erythema multiforme, toxic epidermal necrolysis, and/or Stevens-Johnson syndrome (rare). It is generally recommended to discontinue treatment if severe rash or moderate symptoms accompanied by other systemic symptoms occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Fat redistribution: May cause redistribution of fat (eg, buffalo hump, peripheral wasting with increased abdominal girth, cushingoid appearance).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immune reconstitution syndrome: Patients may develop immune reconstitution syndrome resulting in the occurrence of an inflammatory response to an indolent or residual opportunistic infection during initial HIV treatment or activation of autoimmune disorders (eg, Graves&rsquo; disease, polymyositis, Guillain-Barr&eacute; syndrome) later in therapy; further evaluation and treatment may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Increased cholesterol: Increases in total cholesterol and triglycerides have been reported; screening should be done prior to therapy and periodically throughout treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; PR interval prolongation: Ritonavir has been associated with AV block (including second- and third-degree block) due to prolongation of PR interval; use caution with drugs that prolong the PR interval.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in  patients with cardiomyopathy, ischemic heart disease, pre-existing conduction abnormalities, or structural heart disease; may be at increased risk of conduction abnormalities (eg, second- or third-degree AV block).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Changes in glucose tolerance, hyperglycemia, exacerbation of diabetes, DKA, and new-onset diabetes mellitus have been reported in patients receiving protease inhibitors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hemophilia A or B: Use with caution in patients with hemophilia A or B; increased bleeding events, including spontaneous skin hematoma and hemarthrosis, during protease inhibitor therapy have been reported. Additional factor VIII may be needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: May cause hepatitis, jaundice, and/or exacerbation of pre-existing hepatic dysfunction (including fatalities); use with caution in patients with underlying hepatic disease, such as hepatitis B or C, cirrhosis, or those with high baseline transaminases; consider increased monitoring of transaminases in these patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pancreatitis: Use with caution in patients with increased triglycerides; pancreatitis has been observed (including fatalities). Monitor serum lipase and amylase, and for symptoms of nausea, vomiting, and/or abdominal pain.  Temporary or permanent discontinuation may be clinically indicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Etravirine plus tipranavir or atazanavir or fosamprenavir with &ldquo;boosted&rdquo; ritonavir are not recommended regimens; do not use (DHHS, 2013).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; High potential for interactions:",
"     <b>",
"      [U.S. Boxed Warning]: Ritonavir may interact with many medications, resulting in potentially serious and/or life-threatening adverse events.",
"     </b>",
"     Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Preterm neonates: Oral solution contains ethanol and propylene glycol; ethanol competitively inhibits propylene glycol metabolism; preterm infants may be at increased risk of toxicity due to decreased ability to metabolize propylene glycol. Postmarketing adverse reactions (cardiac toxicity, lactic acidosis, renal failure, CNS depression, respiratory complications, acute renal failure including fatalities) have been reported in preterm neonates receiving ritonavir-containing solutions. Do not use in neonates with a postmenstrual age (first day of mother&rsquo;s last menstrual period to birth plus elapsed time after birth) &lt;44 weeks, unless benefit outweighs risk and neonate is closely monitored (serum creatinine and osmolality, CNS depression, renal toxicity, lactic acidosis, cardiac conduction abnormalities, hemolysis).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bioequivalence: Norvir&reg; tablets are",
"     <b>",
"      not",
"     </b>",
"     bioequivalent to Norvir&reg; capsules. Gastrointestinal side effects (eg, nausea, vomiting, abdominal pain, diarrhea) or paresthesias may be more common when patients are switching from the capsule to the tablet formulation due to a higher C",
"     <sub>",
"      max",
"     </sub>",
"     (26% increase) observed with the tablet formulation compared to the capsule. These side effects may decrease as therapy is continued.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Oral solution: The oral solution contains large amounts of ethanol (43.2%) and propylene glycol (26.57%). Healthcare providers should pay special attention to accurate calculation, measurement, and administration of dose. Overdose (or cumulative ethanol or propylene glycol content in medications) in a child may lead to lethal ethanol or propylene glycol toxicity.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F218789\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (minor), CYP2B6 (minor), CYP2D6 (minor), CYP3A4 (major), P-glycoprotein;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C19 (weak), CYP2C8 (strong), CYP2C9 (weak), CYP2D6 (strong), CYP2E1 (weak), CYP3A4 (strong), P-glycoprotein;",
"     <b>",
"      Induces",
"     </b>",
"     CYP1A2 (weak/moderate), CYP2C9 (weak/moderate), CYP3A4 (weak/moderate)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F218727\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abacavir: Protease Inhibitors may decrease the serum concentration of Abacavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ado-Trastuzumab Emtansine: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Ado-Trastuzumab Emtansine. Specifically, strong CYP3A4 inhibitors may increase concentrations of the cytotoxic DM1 component.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alfuzosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: Protease Inhibitors may increase the serum concentration of Alfuzosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Almotriptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Almotriptan.  Management: Limit initial almotriptan adult dose to 6.25 mg and maximum adult dose to 12.5 mg/24-hrs when used with a strong CYP3A4 inhibitor. Avoid concurrent use in patients with impaired hepatic or renal function.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alosetron: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alosetron.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ALPRAZolam: Protease Inhibitors may increase the serum concentration of ALPRAZolam.  Management: Concurrent use of alprazolam with indinavir is contraindicated.  All patients receiving such a combination should be monitored closely for excessive response to alprazolam.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: Protease Inhibitors may decrease the metabolism of Amiodarone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the absorption of Protease Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Apixaban: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Apixaban.  Management: Apixaban U.S. prescribing information states dose reduction criteria that may be applied under some circumstances. The apixaban Canadian product monograph suggests that any combined use is contraindicated. See full interaction monograph for details.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Strong) may increase the serum concentration of ARIPiprazole.  Management: See full interaction monograph for details.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: CYP2D6 Inhibitors (Strong) may increase the serum concentration of AtoMOXetine.  Management: Initiate atomoxetine at a reduced dose (adult doses -- patients up to 70kg: 0.5mg/kg/day; patients 70kg or more: 40mg/day) in patients receiving a strong CYP2D6 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtorvaSTATin: Protease Inhibitors may increase the serum concentration of AtorvaSTATin.  Management: Maximum adult atorvastatin doses: 20 mg/day with darunavir/ritonavir, fosamprenavir, fosamprenavir/ritonavir, saquinavir/ritonavir; 40 mg/day with nelfinavir; lowest necessary dose with lopinavir/ritonavir.  Avoid atorvastatin with tipranavir/ritonavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atovaquone: Ritonavir may decrease the serum concentration of Atovaquone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Avanafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Avanafil.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Axitinib.  Management: Avoid concurrent use of axitinib with any strong CYP3A inhibitor whenever possible.  If a strong CYP3A inhibitor must be used with axitinib, a 50% axitinib dose reduction is recommended.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bedaquiline: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bedaquiline.  Management: Limit the duration of concomitant administration of bedaquiline with CYP3A4 inhibitors to no more than 14 days, unless the benefit of continued administration is judged to outweigh the possible risks. Monitor for toxic effects of bedaquiline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May decrease the serum concentration of Ritonavir. Ritonavir may decrease the serum concentration of Boceprevir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bortezomib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bortezomib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosentan: Ritonavir may increase the serum concentration of Bosentan.  Management: Use bosentan 62.5 mg daily or every other day in adult patients who have been on ritonavir for at least 10 days.  Temporarily stop bosentan (for at least 36 hrs) before starting ritonavir; wait until at least 10 days on ritonavir before restarting.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brentuximab Vedotin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brinzolamide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brinzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Nasal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Systemic, Oral Inhalation): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Systemic, Oral Inhalation).  Management: Consider reducing the oral budesonide dose when used together with a CYP3A4 inhibitor.  This interaction is likely less severe with orally inhaled budesonide.  Monitor patients closely for signs/symptoms of corticosteroid excess.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BuPROPion: Ritonavir may decrease the serum concentration of BuPROPion. Mixed effects on concentrations of the active hydroxybupropion metabolite have been reported.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cabozantinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cabozantinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Dihydropyridine): Protease Inhibitors may decrease the metabolism of Calcium Channel Blockers (Dihydropyridine).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Clevidipine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): Protease Inhibitors may decrease the metabolism of Calcium Channel Blockers (Nondihydropyridine). Increased serum concentrations of the calcium channel blocker may increase risk of AV nodal blockade.  Management: Avoid concurrent use when possible. If this combination is used, monitor for evidence of toxicity. The manufacturer of atazanavir recommends a 50% dose reduction for diltiazem be considered. Saquinavir or tipranavir use with bepridil is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Canagliflozin: Ritonavir may decrease the serum concentration of Canagliflozin.  Management: Consider increasing canagliflozin dose to 300 mg/day in patients with estimated GFR &gt;60 mL/min/1.73 m2 who tolerate canagliflozin 100 mg/day and require greater glycemic control. Consider alternatives in patients with estimated GFR 45-60 mL/min/1.73 m2.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Protease Inhibitors. Protease Inhibitors may decrease the metabolism of CarBAMazepine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cisapride: Protease Inhibitors may increase the serum concentration of Cisapride. This may result in QTc prolongation and malignant cardiac arrhythmias.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clarithromycin: Protease Inhibitors may diminish the therapeutic effect of Clarithromycin. Specifically, certain protease inhibitors may decrease formation of the active 14-hydroxy-clarithromycin metabolite, which may negatively impact clarithromycin effectiveness vs. H. influenzae and other non-MAC infections. Clarithromycin may increase the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of Clarithromycin. Clarithromycin dose adjustment in renally impaired patients may be needed.  Management: Avoid clarithromycin doses greater than 1000 mg/day when used with a protease inhibitor. Further dose reductions may be needed in patients with impaired renal function. Consider alternative antimicrobial for any non-MAC infection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clorazepate: Ritonavir may increase the serum concentration of Clorazepate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Codeine: CYP2D6 Inhibitors (Strong) may diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine.  Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a strong CYP3A4 inhibitor.  In those with normal renal and hepatic function, reduce colchicine dose as directed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Conivaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): Protease Inhibitors may decrease the serum concentration of Contraceptives (Estrogens).  Management: Use oral contraceptives containing at least 35mcg ethinyl estradiol with atazanavir/ritonavir, or no more than 30mcg in patients receiving atazanavir alone. Use of an alternative, non-hormonal contraceptive is recommended with other protease inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Corticosteroids (Orally Inhaled).  Management: Monitor for signs and symptoms of adrenal suppression if inhaled budesonide or mometasone are coadministered with a strong CYP3A4 inhibitor.  Avoid combining inhaled fluticasone with any strong CYP3A4 inhibitor.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Beclomethasone (Oral Inhalation); Triamcinolone (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Crizotinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Crizotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): May increase the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C8 Substrates: CYP2C8 Inhibitors (Strong) may decrease the metabolism of CYP2C8 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Substrates: CYP2D6 Inhibitors (Strong) may decrease the metabolism of CYP2D6 Substrates.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Tamoxifen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inhibitors (Strong) may decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: P-glycoprotein/ABCB1 Inhibitors may increase serum concentrations of the active metabolite(s) of Dabigatran Etexilate.  Management: Dabigatran dose reductions may be needed.  Specific recommendations vary considerably according to US vs Canadian labeling, specific P-gp inhibitor, renal function, and indication for dabigatran treatment.  Refer to full monograph or dabigatran labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Ritonavir may decrease the serum concentration of Deferasirox.  Management: Avoid combination when possible; if the combination must be used, consider a 50% increase in initial deferasirox dose, with monitoring of serum ferritin concentrations and clinical responses to guide further dosing.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Delavirdine: May increase the serum concentration of Protease Inhibitors. Protease Inhibitors may decrease the serum concentration of Delavirdine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazepam: Ritonavir may increase the serum concentration of Diazepam.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dienogest: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dienogest.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Digoxin: Protease Inhibitors may increase the serum concentration of Digoxin. Increased serum concentrations of digoxin may increase risk of AV nodal blockade.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disulfiram: May enhance the adverse/toxic effect of Ritonavir. This is specific for the lopinavir/ritonavir (Kaletra) oral solution due to its alcohol content (42%). Management: Concomitant use of Kaletra (lopinavir/ritonavir) oral solution and disulfiram should be avoided. Kaletra contains 42% alcohol.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Divalproex: Protease Inhibitors may decrease the serum concentration of Divalproex.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronabinol: Ritonavir may increase the serum concentration of Dronabinol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dronedarone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dutasteride: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dutasteride.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Efavirenz: May enhance the adverse/toxic effect of Ritonavir. Efavirenz may increase the serum concentration of Ritonavir. Ritonavir may increase the serum concentration of Efavirenz.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enfuvirtide: May increase the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of Enfuvirtide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enzalutamide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Enzalutamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Eplerenone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: Protease Inhibitors may decrease the metabolism of Eplerenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: Protease Inhibitors may increase the serum concentration of Ergot Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Cabergoline.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Estazolam: Ritonavir may increase the serum concentration of Estazolam.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etravirine: Ritonavir may decrease the serum concentration of Etravirine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Everolimus.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: CYP3A4 Inhibitors (Strong) may increase the serum concentration of FentaNYL.  Management: Monitor patients extra closely for several days following initiation of the combination, and fentanyl dosage reductions should be made as appropriate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fesoterodine: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Fesoterodine.  Management: Avoid fesoterodine doses greater than 4 mg daily in adult patients who are also receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fesoterodine: CYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Flecainide: Ritonavir may increase the serum concentration of Flecainide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Flurazepam: Ritonavir may increase the serum concentration of Flurazepam.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluticasone (Nasal): Ritonavir may increase the serum concentration of Fluticasone (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluticasone (Oral Inhalation): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fluticasone (Oral Inhalation).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May decrease the serum concentration of Ritonavir. Ritonavir may decrease the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fusidic Acid: May decrease the metabolism of Protease Inhibitors. Protease Inhibitors may decrease the metabolism of Fusidic Acid.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Garlic: May decrease the serum concentration of Protease Inhibitors. Management: Concurrent use of garlic supplements with protease inhibitors is not recommended.  If this combination is used, monitor closely for altered serum concentrations/effects of protease inhibitors, and particularly for signs/symptoms of therapeutic failure.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     GuanFACINE: CYP3A4 Inhibitors (Strong) may increase the serum concentration of GuanFACINE.  Management: Reduce the guanfacine dose by 50% when adding a strong CYP3A4 inhibitor.  Limit the guanfacine dose to 2 mg/day when starting guanfacine in a patient who is taking a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Halofantrine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Halofantrine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iloperidone: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Iloperidone. Specifically, concentrations of the metabolites P88 and P95 may be increased. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Iloperidone.  Management: Reduce iloperidone dose by half when administered with a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: Ritonavir may increase the serum concentration of Itraconazole.  Management: Limit the adult maximum itraconazole dose to 200 mg/day in patients receiving ritonavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ivabradine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ivacaftor.  Management: Decrease ivacaftor dose to 150 mg twice a week in patients also receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ixabepilone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ixabepilone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoconazole (Systemic): Ritonavir may increase the serum concentration of Ketoconazole (Systemic).  Management: Limit the adult maximum ketoconazole dose to 200 mg/day in patients receiving ritonavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     LamoTRIgine: Ritonavir may decrease the serum concentration of LamoTRIgine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lapatinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lapatinib.  Management: If an overlap in therapy cannot be avoided, consider reducing lapatinib dose to 500 mg/day during, and within 1 week of completing, treatment with the strong CYP3A4 inhibitor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linagliptin: Ritonavir may increase the serum concentration of Linagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lomitapide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lovastatin: Protease Inhibitors may increase the serum concentration of Lovastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lovastatin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lovastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lumefantrine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lumefantrine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lurasidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maraviroc: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Maraviroc.  Management: Reduce the adult dose of maraviroc to 150 mg twice daily when used with a strong CYP3A4 inhibitor.  Do not use maraviroc with strong CYP3A4 inhibitors in patients with Clcr less than 30 mL/min.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Meperidine: Protease Inhibitors may enhance the adverse/toxic effect of Meperidine. Protease Inhibitors may decrease the serum concentration of Meperidine. Concentrations of the toxic Normeperidine metabolite may be increased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methadone: Protease Inhibitors may decrease the serum concentration of Methadone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MethylPREDNISolone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of MethylPREDNISolone.  Management: Consider methylprednisolone dose titration and/or adjustments in patients receiving strong CYP3A4 inhibitors (eg, azole antifungals, protease inhibitors) and monitor for  increased steroid related adverse effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoprolol: CYP2D6 Inhibitors may increase the serum concentration of Metoprolol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MetroNIDAZOLE (Topical): May enhance the adverse/toxic effect of Ritonavir. A disulfiram-like reaction could occur due to the alcohol contained in Kaletra (lopinavir/ritonavir) oral solution.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Midazolam: Protease Inhibitors may increase the serum concentration of Midazolam.  Management: Oral midazolam contraindicated with all protease inhibitors.  IV midazolam contraindicated with fosamprenavir and nelfinavir; other protease inhibitors recommend caution, close monitoring, and consideration of lower IV midazolam doses with concurrent use.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Mifepristone.  Management: Limit mifepristone adult dose, when used for treatment of hyperglycemia in Cushing's syndrome, to a maximum of 300 mg/day when combined with a strong CYP3A4 inhibitor. Monitor for increased mifepristone toxicity regardless of dose or indication.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nebivolol: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Nebivolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nefazodone: Protease Inhibitors may increase the serum concentration of Nefazodone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nilotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nisoldipine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nisoldipine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ospemifene: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ospemifene.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paricalcitol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Paricalcitol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pazopanib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pazopanib.  Management: Avoid concurrent use of pazopanib with strong inhibitors of CYP3A4 whenever possible.  If it is not possible to avoid such a combination, reduce pazopanib adult dose to 400 mg.  Further dose reductions may also be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Substrates: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May decrease the serum concentration of Ritonavir. Ritonavir may decrease the serum concentration of Phenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: CYP3A4 Inhibitors (Strong) may decrease the metabolism of Pimecrolimus.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: Protease Inhibitors may decrease the metabolism of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pioglitazone: CYP2C8 Inhibitors (Strong) may increase the serum concentration of Pioglitazone.  Management: Limit pioglitazone adult maximum dose to 15 mg/day when used in combination with any strong CYP2C8 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ponatinib.  Management: Per ponatinib U.S. prescribing information, the starting dose of ponatinib should be reduced to 30 mg daily during treatment with any strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Posaconazole: May increase the serum concentration of Ritonavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prasugrel: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Prasugrel.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PrednisoLONE (Systemic): Ritonavir may increase the serum concentration of PrednisoLONE (Systemic).  Management: Consider prednisolone dose reductions in patients receiving ritonavir and monitor for increased adverse effects with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PredniSONE: Ritonavir may increase the serum concentration of PredniSONE.  Management: Consider prednisone dose reductions in patients receiving ritonavir, and monitor for increased prednisone levels/adverse effects with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Proguanil: Ritonavir may decrease the serum concentration of Proguanil.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: Ritonavir may increase the serum concentration of Propafenone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May increase the serum concentration of other Protease Inhibitors. Management: Atazanavir--indinavir combination contraindicated. Tipranavir/ritonavir or atazanavir/ritonavir not recommended with other protease inhibitors.  Other combos may require dose changes.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prucalopride: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Prucalopride.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Protease Inhibitors may decrease the metabolism of QuiNIDine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNINE: May increase the serum concentration of Ritonavir. Ritonavir may decrease the serum concentration of QuiNINE. This effect has been seen with lopinavir/ritonavir.  The individual contributions of lopinavir and ritonavir to this effect are unclear. Ritonavir may increase the serum concentration of QuiNINE.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ranolazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Red Yeast Rice: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Red Yeast Rice. Specifically, concentrations of lovastatin and related compounds found in Red Yeast Rice may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Regorafenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Regorafenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifabutin: Ritonavir may increase serum concentrations of the active metabolite(s) of Rifabutin. Ritonavir may increase the serum concentration of Rifabutin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifampin: May decrease the serum concentration of Ritonavir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RomiDEPsin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of RomiDEPsin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rosuvastatin: Protease Inhibitors may increase the serum concentration of Rosuvastatin.  Management: Start with the lowest possible rosuvastatin dose and monitor for signs/symptoms of toxicity. In adult patients receiving atazanavir/ritonavir or lopinavir/ritonavir, initiate rosuvastatin at a 5 mg/day and do not exceed a dose of 10 mg/day.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ruxolitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ruxolitinib.  Management: Reduce ruxolitinib initial adult dose to 10 mg twice daily in patients receiving strong CYP3A4 inhibitors whose platelet count is 100*10^9/L or greater.  Avoid in patients with lower platelet count.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salmeterol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Salmeterol.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Saxagliptin.  Management: Saxagliptin U.S. product labeling recommends limiting saxagliptin adult dose to 2.5 mg/day when used with a strong CYP3A4 inhibitor. Monitor for increased saxagliptin levels/effects. A similar recommendation is not made in the Canadian product labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sildenafil: Protease Inhibitors may increase the serum concentration of Sildenafil.  Management: Erectile dysfunction: sildenafil max = 25 mg/48 hrs with ritonavir, atazanavir, or darunavir; starting dose = 25 mg with other protease inhibitors (adult doses).  Contraindicated if sildenafil being used for pulmonary arterial hypertension.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sildenafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Sildenafil.  Management: When used for treatment of pulmonary arterial hypertension, use of sildenafil with strong CYP3A4 inhibitors should be avoided.  When used for erectile dysfunction, starting dose should be reduced to 25 mg.  Max dose with ritonavir is 25 mg per 48 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Silodosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Silodosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Simvastatin: Protease Inhibitors may increase the serum concentration of Simvastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Simvastatin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Simvastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sirolimus: Protease Inhibitors may increase the serum concentration of Sirolimus.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of SORAfenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May increase the metabolism of Protease Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Protease Inhibitors may decrease the metabolism of Tacrolimus (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): Protease Inhibitors may decrease the metabolism of Tacrolimus (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tadalafil: Ritonavir may increase the serum concentration of Tadalafil.  Management: Recommendations regarding use of tadalafil in patients also receiving ritonavir may vary based on indication and/or international labeling. Consult appropriate product labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamoxifen: CYP2D6 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically, strong CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamsulosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tamsulosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: Ritonavir may decrease the serum concentration of Telaprevir. Ritonavir may increase the serum concentration of Telaprevir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Temsirolimus: Protease Inhibitors may enhance the adverse/toxic effect of Temsirolimus. Levels of sirolimus, the active metabolite, may be increased, likely due to inhibition of CYP-mediated metabolism.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tenofovir: May decrease the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of Tenofovir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetrabenazine: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Tetrabenazine. Specifically, concentrations of the active alpha- and beta-dihydrotetrabenazine metabolites may be increased.  Management: Tetrabenazine adult dose should be reduced by 50% when starting a strong CYP2D6 inhibitor.  Maximum tetrabenazine adult dose is 50 mg/day when used with a strong CYP2D6 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Protease Inhibitors may decrease the serum concentration of Theophylline Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dyphylline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thioridazine: CYP2D6 Inhibitors may decrease the metabolism of Thioridazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ticagrelor: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ticagrelor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tofacitinib.  Management: Reduce the adult dose of tofacitinib to 5 mg daily in patients receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolterodine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolterodine.  Management: The maximum recommended dose of long-acting tolterodine is 2 mg/day when used together with a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolvaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topotecan: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Topotecan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: CYP3A4 Inhibitors (Strong) may enhance the adverse/toxic effect of Toremifene. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Toremifene.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraMADol: CYP2D6 Inhibitors (Strong) may diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Treprostinil: CYP2C8 Inhibitors (Strong) may increase the serum concentration of Treprostinil.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Triamcinolone (Systemic): Ritonavir may enhance the adverse/toxic effect of Triamcinolone (Systemic). Specifically, risks of developing iatrogenic Cushing syndrome and secondary adrenal insufficiency may be increased. Ritonavir may increase the serum concentration of Triamcinolone (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Triazolam: Protease Inhibitors may increase the serum concentration of Triazolam.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: Protease Inhibitors may increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: Protease Inhibitors may decrease the serum concentration of Valproic Acid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vardenafil: Protease Inhibitors may increase the serum concentration of Vardenafil.  Management: Limit vardenafil adult dose to max of 2.5 mg/72 hrs with ritonavir, atazanavir, or darunavir; limit to max adult dose of 2.5 mg/24 hrs with other protease inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vardenafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vardenafil.  Management: Recommendations regarding concomitant use of vardenafil with strong CYP3A4 inhibitors may vary depending on brand name (e.g., Levitra, Staxyn) or by international labeling. Consult appropriate product labeling for specific recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vemurafenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vemurafenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vilazodone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vilazodone.  Management: Limit maximum adult vilazodone dose to 20 mg/day in patients receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinBLAStine: Ritonavir may increase the serum concentration of VinBLAStine.  Management: Monitor closely for signs and symptoms of vinblastine toxicity; consider temporary interruption of ritonavir antiviral therapy if patients develop significant toxicity with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine: Ritonavir may increase the serum concentration of VinCRIStine.  Management: Monitor closely for signs and symptoms of vincristine toxicity; consider temporary interruption of ritonavir antiviral therapy if patients develop significant toxicity with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: Ritonavir may decrease the serum concentration of Voriconazole.  Management: Concurrent voriconazole and high-dose ritonavir (adult doses of 400 mg every 12 hrs or greater) is contraindicated.  Voriconazole with lower-dose ritonavir should be avoided unless benefits outweigh risk of inadequate voriconazole concentrations.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Warfarin: Ritonavir may decrease the serum concentration of Warfarin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zidovudine: Protease Inhibitors may decrease the serum concentration of Zidovudine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zuclopenthixol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Zuclopenthixol.  Management: Consider zuclopenthixol dosage reduction with concomitant use of a strong CYP3A4 inhibitor (eg, ketoconazole) in poor CYP2D6 metabolizers or with strong CYP2D6 inhibitors (eg, paroxetine). Monitor for increased zuclopenthixol levels/toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F218754\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Food enhances absorption. Management: Manufacturer recommends taking with food. Maintain adequate hydration, unless instructed to restrict fluid intake.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John's wort may decrease ritonavir serum levels. Garlic may decrease the serum concentration of ritonavir. Management: Avoid St John's wort; concurrent use is contraindicated. Garlic supplementation is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F218729\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F218743\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in animal reproduction studies only with doses which were also maternally toxic. Ritonavir crosses the placenta in minimal amounts; no increased risk of overall birth defects has been observed following first trimester exposure according to data collected by the antiretroviral pregnancy registry. Early studies have shown lower plasma levels during pregnancy compared to postpartum. The DHHS Perinatal HIV Guidelines consider ritonavir to be a preferred protease inhibitor (PI) for use during pregnancy when used as a booster for other PIs. The oral solution contains alcohol and therefore may not be the best formulation for use in pregnancy. A small increased risk of preterm birth has been associated with maternal use of protease inhibitor-based combination antiretroviral (ARV) therapy during pregnancy; however, the benefits of use generally outweigh this risk and PIs should not be withheld if otherwise recommended. Hyperglycemia, new onset of diabetes mellitus, or diabetic ketoacidosis have been reported with protease inhibitors; it is not clear if pregnancy increases this risk.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Regardless of CD4 count or HIV RNA copy number, all HIV-infected pregnant women should receive a combination antepartum ARV drug regimen; this includes women who require therapy for their own health, as well as women who do not yet require therapy for their own health. ARV therapy should be started as soon as possible if required for the woman&rsquo;s health. Although earlier initiation may be more effective in reducing the perinatal transmission of HIV, also consider maternal conditions (eg, nausea and vomiting) and the potential risks of first trimester fetal exposure for specific agents. Plasma HIV RNA levels should be assessed at ~34-36 weeks gestation in order to help determine mode of delivery. If ARV therapy must be interrupted for &lt;24 hours during the peripartum period, stop then restart all medications simultaneously in order to decrease the chance of developing resistance. Long-term follow-up is recommended for all infants exposed to ARV medications.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Healthcare providers are encouraged to enroll pregnant women exposed to antiretroviral medications in the Antiretroviral Pregnancy Registry (1-800-258-4263 or www.APRegistry.com). Healthcare providers caring for HIV-infected women and their infants may contact the National Perinatal HIV Hotline (888-448-8765) for clinical consultation (DHHS [perinatal], 2012).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F218769\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F218744\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Maternal or infant antiretroviral therapy does not completely eliminate the risk of postnatal HIV transmission. In addition, multiclass-resistant virus has been detected in breast-feeding infants despite maternal therapy. Therefore, in the United States, where formula is accessible, affordable, safe, and sustainable, and the risk of infant mortality due to diarrhea and respiratory infections is low, complete avoidance of breast-feeding by HIV-infected women is recommended to decrease potential transmission of HIV (DHHS [perinatal], 2012).",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F218745\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The manufacturer recommends taking with food. Oral solution contains 43% ethanol by volume.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F218742\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Norvir Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (30): $308.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Norvir Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     80 mg/mL (240 mL): $1728.24",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Norvir Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (30): $308.60",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F218731\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Triglycerides, cholesterol, CBC, LFTs, CPK, uric acid, basic HIV monitoring, viral load, CD4 count, glucose, serum amylase and lipase",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F218746\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Kaletra (MX);",
"     </li>",
"     <li>",
"      Norvir (AE, AT, AU, BE, BG, BH, BR, CH, CL, CN, CO, CR, CY, CZ, DE, DK, EC, EE, EG, ES, FI, FR, GB, GR, GT, HK, HN, HU, ID, IE, IL, IQ, IR, IT, JO, KW, LB, LU, LY, MT, MY, NI, NL, NO, NZ, OM, PA, PE, PL, PT, QA, RU, SA, SE, SG, SK, SV, SY, TH, TR, TW, VE, YE);",
"     </li>",
"     <li>",
"      Rifaxi (AR);",
"     </li>",
"     <li>",
"      Ritovir (IN, UY)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F218721\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Binds to the site of HIV-1 protease activity and inhibits cleavage of viral Gag-Pol polyprotein precursors into individual functional proteins required for infectious HIV. This results in the formation of immature, noninfectious viral particles.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F218738\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Variable; increased with food; In the fed state, mean C",
"     <sub>",
"      max",
"     </sub>",
"     of the tablet formulation increased by 26% compared to the capsule.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: High concentrations in serum and lymph nodes; V",
"     <sub>",
"      d",
"     </sub>",
"     : 0.16-0.66 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 98% to 99%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via CYP3A4 and 2D6; five metabolites, low concentration of an active metabolite (M-2) achieved in plasma (oxidative)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 3-5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: Oral solution: 2 hours (fasted); 4 hours (nonfasted)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (~11%, ~4% as unchanged drug); feces (~86%, ~34% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Danner SA, Carr A, Leonard JM, et al, &ldquo;A Short-Term Study of the Safety, Pharmacokinetics, and Efficacy of Ritonavir, an Inhibitor of HIV-1 Protease. European-Australian Collaborative Ritonavir Study Group,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1995, 333(23):1528-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/58/12202/abstract-text/7477167/pubmed\" id=\"7477167\" target=\"_blank\">",
"        7477167",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Deeks SG, Smith M, Holodniy M, et al, &ldquo;HIV-1 Protease Inhibitors. A Review for Clinicians,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1997, 277(2):145-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/58/12202/abstract-text/8990341/pubmed\" id=\"8990341\" target=\"_blank\">",
"        8990341",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents, &ldquo;Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents, Department of Health and Human Services,&rdquo; February 12, 2013;1-267. Available at",
"      <a href=\"file://aidsinfo.nih.gov/Guidelines/GuidelineDetail.aspx?GuidelineID=7&amp;ClassID=1\" target=\"_blank\">",
"       file://www.aidsinfo.nih.gov",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DHHS Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission, \"Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States,\"  July 31, 2012. Available at",
"      <a href=\"file://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf\" target=\"_blank\">",
"       file://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hilts AE and Fish DN, &ldquo;Dosage Adjustment of Antiretroviral Agents in Patients With Organ Dysfunction,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 1998, 55:2528-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/58/12202/abstract-text/9853641/pubmed\" id=\"9853641\" target=\"_blank\">",
"        9853641",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hsu A, Granneman GR, Cao G, et al, &ldquo;Pharmacokinetic Interactions Between Two Human Immunodeficiency Virus Protease Inhibitors, Ritonavir and Saquinavir,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1998, 63(4):453-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/58/12202/abstract-text/9585800/pubmed\" id=\"9585800\" target=\"_blank\">",
"        9585800",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kakuda TN, Struble KA, and Piscitelli SC, &ldquo;Protease Inhibitors for the Treatment of Human Immunodeficiency Virus Infection,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 1998, 55(3):233-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/58/12202/abstract-text/9492254/pubmed\" id=\"9492254\" target=\"_blank\">",
"        9492254",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kaufman MB and Simionatto C, &ldquo;A Review of Protease Inhibitor-Induced Hyperglycemia,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 1999, 19(1):114-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/58/12202/abstract-text/9917085/pubmed\" id=\"9917085\" target=\"_blank\">",
"        9917085",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kaul DR, Cinti SK, Carver PL, et al, &ldquo;HIV Protease Inhibitors: Advances in Therapy and Adverse Reactions, Including Metabolic Complications,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 1999, 19(3):281-98.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/58/12202/abstract-text/10221367/pubmed\" id=\"10221367\" target=\"_blank\">",
"        10221367",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lea AP and Faulds D, &ldquo;Ritonavir,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1996, 52(4):541-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/58/12202/abstract-text/8891466/pubmed\" id=\"8891466\" target=\"_blank\">",
"        8891466",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McDonald CK and Kuritzkes DR, &ldquo;Human Immunodeficiency Virus Type 1 Protease Inhibitors,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 1997, 157(9):951-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/58/12202/abstract-text/9140265/pubmed\" id=\"9140265\" target=\"_blank\">",
"        9140265",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mueller BU, Zuckerman J, Nelson J, et al, &ldquo;A Phase I/II Study of the Protease Inhibitor Ritonavir (ABT-538) in Children With HIV Infection,&rdquo;",
"      <i>",
"       Int Conf AIDS",
"      </i>",
"      , 1996, 11:37.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rana KZ and Dudley MN, &ldquo;Human Immunodeficiency Virus Protease Inhibitors,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 1999, 19(1):35-59.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/58/12202/abstract-text/9917077/pubmed\" id=\"9917077\" target=\"_blank\">",
"        9917077",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rhone SA, Hogg RS, Yip B, et al, &ldquo;The Antiviral Effect of Ritonavir and Saquinavir in Combination Amongst HIV Infected Adults: Results From a Community-Based Study,&rdquo;",
"      <i>",
"       AIDS",
"      </i>",
"      , 1998, 12(6):619-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/58/12202/abstract-text/9583602/pubmed\" id=\"9583602\" target=\"_blank\">",
"        9583602",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children, &ldquo;Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection,&rdquo; August 16, 2010. Available at",
"      <a href=\"file://www.aidsinfo.nih.gov\" target=\"_blank\">",
"       file://www.aidsinfo.nih.gov",
"      </a>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9871 Version 51.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-FE77A46CF4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_58_12202=[""].join("\n");
var outline_f11_58_12202=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709403\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218758\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218759\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218795\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218763\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218779\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218764\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16361016\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218765\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218733\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218718\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218736\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218734\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16360985\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218803\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218793\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218739\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218722\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218789\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218727\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218754\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218729\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218743\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218769\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218744\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218745\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218742\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218731\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218746\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218721\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218738\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9871\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9871|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?5/35/5686?source=related_link\">",
"      Ritonavir: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?6/9/6298?source=related_link\">",
"      Ritonavir: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_58_12203="Medical Rx pain endometriosis";
var content_f11_58_12203=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F69477&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F69477&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Medical treatment for pelvic pain in endometriosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Advantages",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Avoids risk of damaging pelvic organs during surgery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Avoids risk of postoperative adhesion formation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Treats implants not visualized during surgery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Disadvantages",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Side effects of medications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        High recurrence rates after discontinuation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No effect on existing adhesions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No effect on endometriomas",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Treatments involving suppression of ovulation also prevent pregnancy during the treatment period",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No effect on infertility",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_58_12203=[""].join("\n");
var outline_f11_58_12203=null;
var title_f11_58_12204="AML induction regimens";
var content_f11_58_12204=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F78251&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F78251&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Chemotherapy induction regimens for acute myeloid leukemia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drugs",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dosing",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comments",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cytarabine",
"        <strong>",
"         plus",
"        </strong>",
"        daunorubicin",
"       </td>",
"       <td>",
"        <strong>",
"         Cytarabine",
"        </strong>",
"        : 100 to 300 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        daily as a continuous infusion for 7 days;",
"        <strong>",
"         Daunorubicin",
"        </strong>",
"        : 60 to 90 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        intravenous push on each of the first 3 days of treatment",
"       </td>",
"       <td>",
"        \"Standard 7+3\" induction regimen resulting in approximately 60 to 80 percent remission rate and acceptable toxicity in patients under 60 years old",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Cytarabine (HDAC)",
"        <strong>",
"         plus",
"        </strong>",
"        daunorubicin",
"       </td>",
"       <td>",
"        <strong>",
"         Cytarabine",
"        </strong>",
"        : 1 to 3 g/m",
"        <sup>",
"         2",
"        </sup>",
"        twice daily for a total of 12 doses;",
"        <strong>",
"         Daunorubicin",
"        </strong>",
"        : 45 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        intravenous push for 3 days following cytarabine",
"       </td>",
"       <td>",
"        Yields a 90 percent remission rate; however, substantial toxicity precludes postremission therapy in a high proportion of patients",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Cytarabine",
"        <strong>",
"         plus",
"        </strong>",
"        idarubicin",
"       </td>",
"       <td>",
"        <strong>",
"         Cytarabine",
"        </strong>",
"        : 100 to 200 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        daily as a continuous infusion for 7 days;",
"        <strong>",
"         Idarubicin",
"        </strong>",
"        : 12 to 13 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV push on each of first 3 days of treatment",
"       </td>",
"       <td>",
"        Has produced a greater remission rate (88 versus 70 percent) than cytarabine/daunorubicin in younger patients; appears superior to daunorubicin in patients with hyperleukocytosis; overall survival not clearly superior to \"standard\" regimen",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Overview of common induction therapy regimens for acute myeloid leukemia in younger adults.",
"    <div class=\"footnotes\">",
"     HDAC: high dose cytarabine.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_58_12204=[""].join("\n");
var outline_f11_58_12204=null;
var title_f11_58_12205="Dosing antituberculous therapy";
var content_f11_58_12205=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F55736&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F55736&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Dosing of antituberculous therapy in adults with HIV coinfection",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Drug",
"      </td>",
"      <td class=\"subtitle1\">",
"       Daily",
"      </td>",
"      <td class=\"subtitle1\">",
"       <p>",
"        2x/wk",
"       </p>",
"       <p>",
"        (not recommended for patients with CD4+ count &lt;100 cells/&micro;L)",
"       </p>",
"      </td>",
"      <td class=\"subtitle1\">",
"       3x/wk",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Isoniazid",
"       </strong>",
"      </td>",
"      <td>",
"       5 mg/kg (usual dose 300 mg)",
"      </td>",
"      <td>",
"       15 mg/kg (usual dose 900 mg)",
"      </td>",
"      <td>",
"       15 mg/kg (usual dose 900 mg)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Rifampin",
"       </strong>",
"       &bull;",
"      </td>",
"      <td>",
"       10 mg/kg (usual dose 600 mg)",
"      </td>",
"      <td>",
"       10 mg/kg (usual dose 600 mg)",
"      </td>",
"      <td>",
"       10 mg/kg (usual dose 600 mg)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\">",
"       Rifabutin (w/o HIV PIs or NNRTI&loz;)",
"      </td>",
"      <td>",
"       5 mg/kg (usual dose 300 mg)",
"      </td>",
"      <td>",
"       5 mg/kg (usual dose 300 mg)",
"      </td>",
"      <td>",
"       5 mg/kg (usual dose 300 mg)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       w/ HIV protease inhibitors",
"      </td>",
"      <td>",
"       150 mg&Delta;",
"      </td>",
"      <td>",
"       Not recommended&Delta;",
"      </td>",
"      <td>",
"       150 mg&Delta;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       w/ efavirenz",
"      </td>",
"      <td>",
"       450-600 mg",
"      </td>",
"      <td>",
"       450-600 mg",
"      </td>",
"      <td>",
"       450-600 mg",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Streptomycin/amikacin/kanamycin",
"       </strong>",
"      </td>",
"      <td>",
"       15 mg/kg",
"      </td>",
"      <td>",
"       25 mg/kg",
"      </td>",
"      <td>",
"       25 mg/kg",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"4\">",
"       Pyrazinamide",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       40-55 kg body weight",
"      </td>",
"      <td>",
"       1,000 mg (18.2-25.0 mg/kg)",
"      </td>",
"      <td>",
"       2,000 mg (36.4-50.0 mg/kg)",
"      </td>",
"      <td>",
"       1,500 mg (27.3-37.5 mg/kg)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       56-75 kg body weight",
"      </td>",
"      <td>",
"       1,500 mg (20.0-26.8 mg/kg)",
"      </td>",
"      <td>",
"       3,000 mg (40.0-53.6 mg/kg)",
"      </td>",
"      <td>",
"       2,500 mg (33.3-44.6 mg/kg)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &gt;75 kg body weight",
"      </td>",
"      <td>",
"       2,000 mg (22.2-26.3 mg/kg)",
"      </td>",
"      <td>",
"       4,000 mg (44.4-52.6 mg/kg)",
"      </td>",
"      <td>",
"       3,000 mg (33.3-44.6 mg/kg)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"4\">",
"       Ethambutol",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       40-55 kg body weight",
"      </td>",
"      <td>",
"       800 mg (14.5-20.0 mg/kg)",
"      </td>",
"      <td>",
"       2,000 mg (36.4-50.0 mg/kg)",
"      </td>",
"      <td>",
"       1,200 mg/kg (21.8-30.0 mg/kg)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       56-75 kg body weight",
"      </td>",
"      <td>",
"       1,200 mg (16.0-21.0 mg/kg)",
"      </td>",
"      <td>",
"       2,800 mg (37.3-50.0 mg/kg)",
"      </td>",
"      <td>",
"       2,000 mg/kg (26.7-35.7 mg/kg)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &gt;75 kg body weight",
"      </td>",
"      <td>",
"       1,600 mg (17.8-21.0 mg/kg)",
"      </td>",
"      <td>",
"       4,000 mg (44.4-52.6 mg/kg)",
"      </td>",
"      <td>",
"       2,400 mg/kg (26.7-31.6 mg/kg)",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Some experts recommend that for severe tuberculosis infection (eg, CNS, pericardial disease) considerations should be given to the use of adjuvant corticosteroids. The dosing and taper schedule should be individualized according to severity of disease and adjusted, as needed, in response to treatment.",
"     <br>",
"      &bull; Rifampin is not recommended in patients receiving HIV protease inhibitor(s) (PI) or the CCR5 antagonist maraviroc.",
"      <br>",
"       &Delta; Acquired rifamycin resistance has been reported in patients with inadequate rifabutin levels while on 150 mg twice weekly dosing together with ritonavir-boosted PIs. May consider therapeutic drug monitoring when rifabutin is used with a ritonavir-boosted PI and adjust dose accordingly.",
"       <br>",
"        &loz; Non-nucleoside reverse transcriptase inhibitor.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Kaplan, JE, Benson, C, Holmes, KH, et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: Recommendations for CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009: 58:1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_58_12205=[""].join("\n");
var outline_f11_58_12205=null;
var title_f11_58_12206="Epidemiology of Campylobacter";
var content_f11_58_12206=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F56850&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F56850&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Incidence of Campylobacter enteritis in the United States, by age",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 388px; height: 272px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Reported campylobacter isolations by age and sex in the United States from 1982 to 1986. There is a high incidence in early childhood (with a peak in the first three months) and a pronounced secondary peak in young adults, a feature not seen with salmonella or shigella infection.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Tauxe RV. Epidemiology of Campylobacter enteritis in the United States, American Society for Microbiology, Washington, DC, 1992, p. 9.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_58_12206=[""].join("\n");
var outline_f11_58_12206=null;
var title_f11_58_12207="The effects of various therapies and treatment in diabetic dogs";
var content_f11_58_12207=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F86383&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F86383&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 480px\">",
"   <div class=\"ttl\">",
"    The effects of various therapies and methods of treatment in diabetic dogs",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 460px; height: 704px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) This graph shows the effects of various antihypertensive therapies on afferent and efferent arteriolar tone in unilaterally nephrectonized diabetic hypertensive dogs.",
"    <br/>",
"    (B) This graph shows the effects of an ace inhibitor or calcium blocker on mesangial matrix proliferation in diabetic dogs.",
"    <div class=\"footnotes\">",
"     * p &lt;0.05 compared to control.",
"     <br>",
"      &Delta; p &lt;0.05 compared to DM alone.",
"      <br>",
"       <font class=\"lozenge\">",
"        &loz;",
"       </font>",
"       p &lt;0.01 compared to DM.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     (A) Adapted by permission from Macmillan Publishers Ltd: Kidney International. Brown SA, Walton CL, Crawford P, Bakris GL. Long-term effects of antihypertensive regimens on renal hemodynamics and proteinuria. Kidney Int 1993; 43:1210.",
"     <a href=\"file://www.nature.com/ki/index.html\" style=\"FONT-STYLE: italic\" target=\"_blank\">",
"      file://www.nature.com/ki/index.html",
"     </a>",
"     . Copyright &copy; 1993.",
"     <br>",
"      (B) Adapted by permission from Macmillan Publishers Ltd: Kidney International. Gaber L, Walton C, Brown S, Bakris G. Effects of different antihypertensive treatments on morphologic progression of diabetic nephropathy in uninephrectomized dogs. Kidney Int 1994; 46:161.",
"      <a href=\"file://www.nature.com/ki/index.html\" style=\"FONT-STYLE: italic\" target=\"_blank\">",
"       file://www.nature.com/ki/index.html",
"      </a>",
"      . Copyright &copy; 1994.",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_58_12207=[""].join("\n");
var outline_f11_58_12207=null;
